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Herbal products have been shown to cause serious interactions when combined with 
conventional medications. A majority of these interactions are pharmacokinetic in nature 
and involve alteration in the activity of drug metabolizing enzymes.  Valerian is a popular 
herbal product often used to treat insomnia and anxiety. Valerian extracts contain 
essential oils with sesquiterpenes such as valerenic acid and its derivatives. However, the 
drug interaction potential of valerian preparations is largely unknown. In human liver 
microsomes, valerenic acid forms a glucuronide conjugate suggesting that valerian 
extracts could interact with drugs that undergo glucuronidation. As glucuronidation is 
catalyzed by UDP- glucuronosyltransferase enzymes (UGT), the goal of this dissertation 
was to investigate the effect of valerian extracts on UGT activity. Acetaminophen was 
used as a probe substrate to measure UGT activity in these studies. A bioassay-guided 
fractionation approach was adopted to identify the major compounds in valerian extracts 
that are responsible for inhibition of UGT activity. The alcoholic extract of valerian was 
fractionated by liquid-liquid extractions followed by chromatographic methods. The 
organic extracts showed significant inhibitory activity compared to the aqueous extracts. 
Using various chromatographic and spectroscopic techniques, the major compounds 
present in the active fraction were identified as valerenic acid, acetoxyvalerenic acid and 
valerenal. The clinical implications of the inhibition of UGT enzymes by valerian 
extracts were investigated in a study in healthy human volunteers. Valerian 
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administration resulted in an increased acetaminophen maximum plasma concentration 
(Cmax) and a decrease in time to reach the maximum plasma concentration (tmax), but did 
not affect the area under the plasma concentration-time curve (AUC) or half life. As these 
results were unexpected, human hepatocyte cultures were used to determine if enzyme 
induction potential of some components may offset the inhibition of UGT enzymes. We 
hypothesized that the inhibition observed in the microsomal study could be masked by an 
increase in enzyme activity due to induction of enzymes by chronic exposure to the 
extracts.  In human hepatocyte cultures, valerian extracts inhibited UGT activity on acute 
exposure while chronic exposure increased UGT activity and mRNA levels. Our study 
indicates that there is no clinically significant interaction between acetaminophen and 
valereian. In vitro studies in human hepatocytes may better predict in vivo herb-drug 
interactions than studies in microsomes. 
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1.0  INTRODUCTION 
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 1.1 HERBAL PRODUCTS AND SAFETY 
There is widespread use of botanicals in the U.S. population with an estimated one-third of 
adults admitting to the use of herbal products (Johnston 1997). The past decade has seen an 
unprecedented increase in the use of herbal remedies with sales exceeding $350 million in 1997 
(Brevoort 1998; Blumenthal 2002). Herbal supplement use continues to grow significantly, with 
sales up by 50% from 1997 to 2002 (Tindle, Davis et al. 2005). Herbal remedies are often 
perceived as natural and therefore, inherently safe. Reports indicate that patients use herbs for a 
wide range of health problems, such as boosting the immune system, improving memory, and 
treating insomnia, depression, or diabetes (Kuo, Hawley et al. 2004). Some of the most 
commonly used herbs are St. John’s wort, Chammomile, Gingko biloba, Echinacea, Ginseng, 
black cohosh and valerian (O'Hara, Kiefer et al. 1998). Prescription drug users may combine 
them with herbal remedies and approximately 70% of the individuals do not disclose herbal use 
to their physicians (Eisenberg, Kessler et al. 1993; Miller 1998; Kaye, Clarke et al. 2000; 
Kaufman, Kelly et al. 2002). In addition, herbal supplements are often complex mixtures of a 
multitude of pharmacologically active compounds. These factors increase the likelihood of herb-
drug interactions and raise concerns about the safety of these products.  
1.2 DRUG INTERACTIONS 
A drug interaction is defined as the modulation of the pharmacological activity of a drug by 
the prior or concomitant administration of another drug (May 1997). The pharmacological 
activity of a drug may also be altered by other exogenous compounds of environmental or 
dietary origin. The pharmacological change can be mediated by two mechanisms: first, by 
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modulation of the pharmacodynamic properties of the drug and second by affecting the 
pharmacokinetics.   
1.2.1 Pharmacodynamic interactions 
A pharmacodynamic interaction occurs between two entities when they both bind to the 
same receptor or have the same pharmacological effect. These interactions can be additive or 
antagonistic. Pharmacodynamic interactions between herbs and narrow therapeutic index drugs, 
such as digoxin, phenobarbital, phenytoin and warfarin are well documented (1970; Miller 
1998). Several herbal remedies have been associated with altered bleeding times in patients 
concurrently taking warfarin. Many of these products have a coumarin component such as dong 
quai (Page and Lawrence 1999) and fenugreek (Lambert and Cormier 2001)), while others 
contain different constituents with antiplatelet effects such as danshen ginko and ginger (Lo, 
Chan et al. 1992; Lo, Chan et al. 1995; Yu, Chan et al. 1997; Yuan, Wei et al. 2004). A 
pharmacodynamic mechanism has been suggested for the interaction of kava with 
benzodiazepines by interference with gamma amino butyric acid (GABA) receptors (Almeida 
and Grimsley 1996). Pharmacodynamic interactions are common with sedatives and hypnotics 
by receptor antagonist or agonist actions. St. John’s wort has been shown to potentiate the effect 
of buspirone as well as serotonin re-uptake inhibitors possibly by inhibiting 4-hydroxytryptamine 
reuptake (Gordon 1998; Lantz, Buchalter et al. 1999; Prost, Tichadou et al. 2000; Dannawi 
2002).  
1.2.2 Pharmacokinetic interactions 
A pharmacokinetic interaction is defined as the alteration in the absorption, distribution, 
metabolism or elimination of one drug by another exogenous compound, such as a drug, food or 
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herb. Of these mechanisms, a majority of pharmacokinetic interactions are attributed to those 
occurring through changes in metabolism. Drug metabolism has conventionally been categorized 
into two phases (Lin and Lu 1997). Phase I reactions, also called functionalization reactions, are 
mainly oxidative reactions catalyzed by cytochrome P450 (CYP) enzymes resulting in 
hydroxylation or demethylation.  Phase II reactions involve the conjugative enzyme families 
such as the UDP-glucuronosyltransferases (UGTs), glutathione-S transferases (GSTs), 
sulfotransferases (STs), and N-acetyltransferases (NATs)(Parkinson 1996).  
The focus of drug-drug and herb-drug interactions has remained on the CYP family of 
enzymes. Among herbal supplements, the best documented herb–drug interactions are that of St. 
John’s wort (Hypericum perforatum) (Roby, Dryer et al. 2001; Karyekar, Eddington et al. 2002; 
Wang, Hamman et al. 2002; Markowitz, Donovan et al. 2003; Wenk, Todesco et al. 2004). In 
vitro studies have shown that hyperforin, considered an active constituent of St. John’s wort, 
induces CYP3A4 and increases the activity of the transporter P-glycoprotein in the gut and 
intestine (Moore, Goodwin et al. 2000; Wang, Hamman et al. 2002; Komoroski, Zhang et al. 
2004; Mannel 2004; Zhou, Lim et al. 2004). The first human study confirming this effect was 
published in 1997 (Kerb, Bauer et al. 1997).  Subsequent studies have shown that administration 
of St. John’s wort can substantially reduce the potency of a wide range of drugs including the 
immunosuppressants cyclosporine and tacrolimus (Ruschitzka, Meier et al. 2000; Ahmed, 
Banner et al. 2001; Beer and Ostermann 2001; Bauer, Stormer et al. 2003; Mai, Stormer et al. 
2003), the HIV protease inhibitor indinavir (Piscitelli, Burstein et al. 2000) and the anti-cancer 
agent imatinib mesylate (Frye, Fitzgerald et al. 2004; Smith 2004). Recent studies suggest that 
Echinacea could interact with substrates of CYP3A4 and CYP1A2 enzymes (Gorski, Huang et 
al. 2004; Gurley, Gardner et al. 2004). In vitro studies indicate that Kava (piper methysticum) 
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could also cause drug interactions by inhibition of CYP2C9, 2C19, 2D6 and 3A4 enzymes 
(Mathews, Etheridge et al. 2002; Unger, Holzgrabe et al. 2002; Zou, Henderson et al. 2004).  
While there is substantial evidence that interactions mediated by phase I enzymes are 
important, there is limited information on the role of phase II enzymes in drug interactions. 
Various compounds have been identified as inhibitors and inducers of UGT isozymes. Inhibitors 
of UGTs include NSAIDs, benzodiazepines, and tricyclic antidepressants.  Immunosuppressants 
such as cyclosporine and tacrolimus are potent inhibitors of UGTs (Zucker, Rosen et al. 1997; 
Zucker, Tsaroucha et al. 1999). Some case reports suggest that a drug interaction occurs between 
sertraline and lamotrigine due to inhibition of glucuronidation by sertraline (Kaufman and 
Gerner 1998). Phenobarbital has been used as a UGT inducer to correct hyperbilirubinemia in 
patients with Crigler-Najjar syndrome. Other drugs known to induce UGTs include 
carbamezepine and phenytoin (Anderson 1998). Oral contraceptives have also been shown to 
induce UGTs leading to increased clearance of lamotrigine (Sabers, Buchholt et al. 2001). This 
interaction resulted in the re-occurrence of seizures or increased seizure frequency in epileptic 
patients.  Induction of UGTs by dietary compounds such as flavonoids is well documented. The 
flavonoid chrysin is a potent inducer of UGT1A1. Other dietary inducers of UGTs are 
cruciferous vegetables such as brussels sprouts and broccoli (van der Logt, Roelofs et al. 2003; 
Walters, Young et al. 2004). Epidemiological studies in pursuit of anti-cancer strategies provide 
evidence of induction of phase II enzymes by various compounds of phytochemical and 
environmental origin such cigarette smoke (Paolini and Nestle 2003).  Exposure to these 
compounds could potentially modulate the concentration of drugs undergoing metabolism via 
phase II pathways. Therefore, the role of UGT enzymes in xenobiotic metabolism and drug 
interactions requires further investigation.     
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1.3 VALERIAN  
Valerian is frequently listed among the ten most widely used herbal supplements (Morris 
and Avorn 2003). Historically, valerian has been used as a sedative, anti-spasmodic, carminative 
and mild analgesic (Davidson and Connor 2000). The use of valerian to alleviate insomnia and 
nervous disorders has been reported (Kiesewetter and Muller 1958; Last 1969; Houghton 1999; 
LaFrance, Lauterbach et al. 2000; Krystal and Ressler 2001). It is often combined with hops 
(humulus lupus), lemon balm (Melissa officinalis), chamomile (Chamaemelum nobile), Kava 
kava (Piper methysticum) or St. John’s wort (Hypericum perforatum)(Davidson and Connor 
2000). Table 1 summarizes the various pathological conditions treated with valerian. 
1.3.1 Formulations and dose 
The herb is available as a capsule, tablet, tea or tincture. Valerian dosing varies and the 
recommendations range from 100-300 mg of extract once a day for anxiety and 300-900 mg for 
insomnia (Davidson and Connor 2000).  In the case of fresh herb, the recommended dose is 2-3 g 
of the dried valerian root soaked in one cup of hot water for 10-15 minutes (Kush, Bleicher et al. 
1998; Schulz, Hansel et al. 1998). 
1.3.2 Pharmacognosy and chemistry 
Valerian belongs to the family Valerianaceae and genus Valeriana.  Valeriana officinalis is 
the species commonly used in the commercial preparations. Other species such as V. wallichi 
(Indian valerian), V. edulis (Mexican valerian) and Nardostachys chinensis (Chinese) are also 
used medicinally (Schultz and Eckstein 1962; Martinez 1969; Holzl and Jurcic 1975; Bagchi, 
Oshima et al. 1988; Herrera-Arellano, Luna-Villegas et al. 2001). Extracts from the roots and 
rhizomes  
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 Table 1  Summary of pathophysiological conditions treated with valerian 
 
 
Sedative effects   
 
Antispasmodic   
 
Gastrointestinal   
 
Emotional Stress 
Insomnia 
Nervousness 
Anxiety 
Nervous heart conditions 
Children’s anorexia 
Restlessness 
Trembling 
Tension headaches  
Graves disease  
Hypochondria 
Excitability 
 
 
 
Muscular pain 
Menstrual cramps 
Bronchial spasms 
Coughs 
 
 
     Digestive disturbances 
Stomach cramps 
Diarrhea 
Bloating 
Colic 
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are used in the preparation of phytomedicines. The presence of valerenic acid and its derivatives 
(acetoxyvalerenic acid and hydroxyvalerenic acid) are characteristic to V. officinalis and its 
subspecies (Bos, Woerdenbag et al. 1997; Letchamo, Ward et al. 2004). Other constituents in 
valerian include epoxy iridoid esters (valepotriates), their decomposition products such as 
baldrinal and homobaldrinal, amino acids (arginine, GABA, glutamine, tyrosine), essential oils 
(borneol, pinene, camphene) and alkaloids (Hansel and Schulz 1981). Recent chemical 
investigations have identified the presence of lignans and a bi-cyclic sesquiterpene acid (epoxy 
valerenic acid)(Dharmaratne, Nanayakkara et al. 2002; Schumacher, Scholle et al. 2002).  
 
 
 
 
 
 
 
 
Figure 1   Valerenic acid 
Valerian also contains small amounts of phenolic acids and flavonoids, valerosidatum, 
chlorogenic acid, caffeic acid, choline, β-sitosterol, fatty acids, and various minerals (2004). 
Commercial formulations are often standardized to valerenic acid content as it is believed to be 
primarily responsible for the sedative effect.  
CH3
COOH
CH3
CH3
1.3.3 Pharmacology 
The sedative effects of valerian have been evaluated in a number of clinical trials. Some 
studies indicate that valerian can improve sleep latency although no change was observed in the 
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electroencephalographs (Stevinson and Ernst 2000).  The mechanism of the sedative effect 
remains elusive and several mechanisms have been proposed including GABA receptor agonist 
effects of valerenic acid and inhibition of GABA-transaminase, the enzyme system responsible 
for the central catabolism of GABA, by valerenic acids and valepotriates (Hansel and Schulz 
1981; Koch 1982; Riedel, Hansel et al. 1982; Bodesheim and Holzl 1997). In addition, aqueous 
valerian extracts have been shown to cause the release of GABA as well as inhibit the reuptake 
of GABA into presynaptic terminals and surrounding glial cells in animal studies (Santos, 
Ferreira et al. 1994). However, recent studies postulate that the effects are also due to some of 
the other constituents like lignans and their binding to serotonin receptors and adenosine 
receptors (Schumacher, Scholle et al. 2002; Dietz, Mahady et al. 2005).       
1.3.4 Valerian-drug Interactions 
As opposed to some popular herbs such as St. John’s Wort or Kava-kava, reports of drug 
interactions and pharmacokinetic studies with valerian or its constituents are scarce. Early animal 
studies investigated the interaction between valerian and barbiturates. These studies showed that 
valepotriates may prolong phenobarbital-induced sleep time. In mice, oral administration of 
valepotriates inhibited methacetin metabolism indicating possible interactions of valerian 
extracts with cytochrome P450 substrates (Braun, Dittmar et al. 1984; von der Hude, 
Scheutwinkel-Reich et al. 1986). Recent studies with expressed enzyme systems have shown that 
valerenic acids as well as alcoholic extracts inhibit CYP3A4 (Lefebvre, Foster et al. 2004; 
Strandell, Neil et al. 2004).  However, valerian did not alter the pharmacokinetics of the 
CYP3A4 substrate alprazolam in healthy volunteers (Donovan, DeVane et al. 2004).       
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1.3.5 Preliminary studies 
Previous work in our laboratory demonstrated that valerenic acid and alcoholic extracts of 
valerian inhibit the glucuronidation of acetaminophen and other UGT probe substrates(Alkharfy 
2002).  The magnitude of inhibition with the valerian extracts (approximately 70% inhibition) 
was greater than with valerenic acid alone (55%) suggesting other components of the extract 
contributed to the extent of interaction.  The extract constituents that may contribute to the 
inhibition of acetaminophen glucuronidation and the clinical relevance have not been addressed.  
The formation of a glucuronide conjugate of valerenic acid further supported the theory that 
valerenic acid and other compounds present in valerian extracts could inhibit the glucuronide 
formation of drugs.                
1.4 UDP-GLUCURONOSYL TRANSFERASE ENZYMES   
Among the Phase II enzymes, UGTs are known to metabolize the largest number of 
xenobiotics, approximately 35% of all drugs metabolized by phase II detoxification enzymes 
(Evans and Relling 1999) (Figure 2) . UGTs catalyze the glucuronidation of a wide range of 
diverse endogenous and exogenous compounds. Although almost all classes of drugs are 
substrates of UGTs, a substantial number of psychoactive drugs and NSAIDs are known to be 
primarily metabolized to glucuronide conjugates. UGTs are also known to play a critical role in 
the homeostasis of numerous endogenous compounds. A well researched example is that of 
billirubin conjugation. Other endogenous compounds include fatty acids, retinoids, biles acids 
and steroids.  Additionally, UGTs play a significant role in metabolism of compounds derived 
from diet as well as environmental sources such as tobacco smoke. Plant derived medicinal 
agents as well as dietary compounds are known to contain poly-phenolic compounds such as 
phenolic acid, flavonoids, stilbenes and lignans that serve as substrates for UGTs.  Table 2 
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provides a representative listing of endogenous and exogenous compounds that undergo 
glucuronidation. 
                                                    
Figure 2  Enzymes involved in Phase II metabolism 
The relative size of each section in the chart indicates the percentage of drugs 
metabolized by the enzyme. GST, glutathione S-transferase; HMT, histamine 
methyltransferase; NAT, N-acetyltransferase; STs, sulfotransferase; TPMT, 
thiopurine methyltransferase; UGTs, uridine 5΄-triphosphate glucuronosyltransferase. 
(Reprinted with permission from Evans, W. E. and Relling, M. V. Science 1999, 
286(5439): 487-490) Copyright 1999 AAAS. URL: http://www.sciencemag.org/
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 Table 2  Representative substrates of UGT enzymes. 
Xenobiotics Endobiotics 
Drugs 
 
Dietary 
compounds 
 
CNS 
Antidepressants 
Amitriptyline 
Imipramine 
Doxepin 
Trazadone 
Antipsychotics 
Olanzepine 
Chlorpromazine 
Trifluoroperazine 
Haloperidol 
Benzodiazepines  
Lorazepam 
Oxazepam  
Anticonvulsant 
Lamotrigine 
Valproic acid 
 
NSAIDS 
Indenes 
Sulindac  
Indomethicin 
 Profens 
Ibuprofen 
Flurbiprofen 
Ketoprofen  
Others 
Diclofenac 
Naproxen 
 
Flavonoids 
(-) –epicatechin 
Quercetin 
Chrysin 
Emodin 
Genistein 
Curcumin  
Terpenes 
Menthol 
Borneol 
Limonene 
Dihydroartemisinin 
Farnesol 
Stilbene 
Resveratrol 
 
Steroids 
Androsterone 
Estradiol  
Bile acids 
Lithocholic acid 
Hyodeoxycholic acid 
 Retinoids 
t-Retinoic acid 
Hydroxyretinoic acid 
Fatty acids 
Arachidonic acid 
Linoleic acid 
Others 
Billirubin 
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1.4.1 Classification and Nomenclature 
UGTs are a superfamily of enzymes in humans.  The enzymes are classified into two 
families that have been designated UGT1 and UGT2 based on their primary amino acid sequence 
predicted from cloned cDNAs (Burchell, Nebert et al. 1991; Mackenzie, Owens et al. 1997). 
Sequence homology between gene products of the UGT1 and UGT2 families is 38-48% while 
homology between members within each family is over 60%. The dendogram derived from this 
nomenclature is shown in Figure 3 (Burchell 2003). 
UGT1
UGT2
38%
40%
47%
87%
89%
69%
81%
88%
1A6
1A1
1A4
1A5
1A3
1A9
1A10
1A8
1A7
2A1
2A2*
55%
70%
79%
90%
78%
90%
2B4
2B7
2B10
2B11
2B15
2B17  
Figure 3   Phylogenetic tree of human UGT family 
Phylogenetic tree illustratrating the divergence of human UGT family based on amino 
acid sequence deduced from cDNA cloning experiments. * indicates cDNA and 
protein encoding UGT has not been identified in any human tissues (adapted from 
Tukey et. al Molecular Pharmacology 2001, 59(3): 405-414) 
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2   3   4    5
 12p     11p     8         10   13p         9        7          6          5     4      3         2p      1
Exons 1 Common Exons
5'- UTR 3'- UTR
Transcription
Primary transcripts UGT1A1
 Intron 1 
Exon 1       Exons 2, 3, 4, 5
Intron 1
Exon 1                                                           Exons 2, 3, 4, 5
UGT1A8
Splicing
Mature transcripts
UGT1A1
UGT1A8
 
Figure 4  Gene structure and mechanism of transcription of UGT1A enzymes  
The UGT1 gene locus is shown from 5΄ to 3´ as an array of 13 linearly arranged 
exons 1 for UGT 1A genes and pseudogenes (designated as p) in combination with 
the common exons 2, 3, 4, 5. Each Exon 1 contains a proximal 5΄ proximal TATA 
box that allows for independent initiation of transcription generating a series of 
overlapping primary transcripts. The exon 1 of primary transcripts are spliced to the 
common exons to form mature mRNAs (Figure adapted from Gong et. al, 
Pharmacogenetics 2001, 11:357-368) 
 
1.4.2 Gene loci and transcription 
The human UGT1A gene locus has been mapped to a 210 kb region with 17 exons on 
human chromosome 2 (2q37). The UGT1A gene contains 10 tandem variable first exons and a 
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common set of downstream constant exons and it has been predicted that at least nine functional 
proteins may be encoded.  Transcription and RNA processing proceeds by a process of exon 
sharing, where the  amino-terminal is encoded by a unique first exon   (A1, A3, A4, A5, A6, A7, 
A8, A9 and A10) and the carboxyl-terminal portion is encoded by the identical four down stream 
exons (2–5) (Owens and Ritter 1992). The gene structure and mechanism of transcription of 
UGT1A enzymes is represented in Figure 4. In contrast to UGT1 family, the human UGT2 
family proteins are encoded by individual structural genes on chromosome 4 (Monaghan, 
Burchell et al. 1997; Burchell, Soars et al. 2000). The human UGT2 family is further subdivided 
into two subfamilies; UGT2A and UGT2B, which contain two (2A1, 2A2) and seven (2B4, 2B7, 
2B10, 2B11, 2B15, 2B17, and 2B28) members, respectively.  
1.4.3 Cellular Localization of UGT enzymes 
UGTs are located in the lumen of the endoplasmic reticulum and the nuclear envelope of 
cells (Radominska-Pandya, Czernik et al. 1999). Advances in molecular biology have led to the 
detection and characterization of 18 human UGTs to date. Human UGTs range from 529 to 534 
amino acids in length, with the N-terminal portion of the protein located in the lumen of the 
endoplasmic reticulum and the C-terminal portion oriented towards the cytoplasm (Tephly and 
Burchell 1990). The aglycone-binding site is believed to be in the N-terminal portion of the UGT 
protein and this region shows the greatest variability in sequence among UGT isozymes. The C-
terminal region of 15-20 amino acids is relatively conserved and is thought to be the UDPGA 
binding domain. Numerous studies with molecular probes support this model of the UGT 
enzyme topology. The hypothetical localization of the domains of the protein is shown in Figure 
5.  In addition to the structural characteristics, UGT activity is hypothesized to be influenced by 
its association with lipid, restricting access of aglycones to the active site as well as protein-
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protein interactions derived from oligomer formation (Peters, Jansen et al. 1984; Zakim and 
Dannenberg 1992; Ikushiro, Emi et al. 1997; Meech and Mackenzie 1997). 
Cytosol
ER 
membrane
Lumen
Active site
UDPGA Glucuronide 
conjugate
Substrate
 
Figure 5  Hypothetical model of UGT topology depicting dimerization of UGT monomers.  
Figure shows a hetero-dimer with the catalytic unit inside the lumen and formation of 
a proteinaceous channel to allow entry of UDPGA into the lumen. The substrate 
diffuses through the membrane bilayer and the glucuronide conjugate is released 
throught the channel into the cytosol. (Adapted from Radominska-Pandya A et. al. 
Drug Metab. Rev. 1999, 31:817-899 and Miners. J et. al. Annual Review of 
Pharmacology and Toxicology 2004, 44: 1-25 ) 
 
1.4.4 Expression and distribution 
Tissue specific expression of UGT isoforms has been identified with the help of modern 
molecular techniques. The majority of UGTs including 1A1, 1A3, 1A4, 1A6, 1A9, 2B4 and 2B7 
are expressed in the liver (Strassburg, Manns et al. 1997). In addition to the liver, gastrointestinal 
tract and kidneys are known to express drug metabolizing enzymes. In addition to all the UGT 
isoforms expressed in the liver, UGT 1A8 and 1A10 have been detected in the human colon and 
designated as intestinal UGTs (Strassburg, Manns et al. 1998). The isoforms expressed in the 
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kidneys are UGT1A8, UGT1A9, UGT1A10 and UGT2B7 (McGurk, Brierley et al. 1998).  
Experiments with kidney microsomes suggest that the expression of 2B7 levels could approach 
that of the liver (Fisher, Vandenbranden et al. 2000). Other tissues where UGT expression has 
been detected are the ovary, prostate, olfactory tissue, brain and placenta (Turgeon, Carrier et al. 
2001; De Leon 2003). It is apparent that UGT2B transcripts are abundantly expressed in steroid 
sensitive tissues such as the ovary and prostate suggesting a protective role against carcinogenic 
actions of steroids in these organs (Beaulieu, Levesque et al. 1998; Belanger, Hum et al. 1998) 
1.4.5 Biochemical mechanism  
UGT enzymes transfer the glucuronyl group from uridine-5΄-diphosphoglucuronate 
(UDPG) to hydrophobic molecules (or aglycones) (Figure 6). The reaction is initiated by the 
coupling of D-glucose-1-phosphate to UTP to give UDP-glucose, followed by the oxidation of 
the primary alcohol to yield the co-substrate UDP-glucuronic acid (UDPGA). The conjugation 
occurs by an SN2 substitution with both the UDPGA and the aglycone substrate bound to the 
active site of the enzyme (Dutton 1980).  The conjugation reaction occurs at the nucleophilic 
acceptor group on the substrate with an electrophilic anomeric carbon (C-1) of glucuronic acid. 
The resulting product undergoes an inversion of configuration at the anomeric carbon (Jakoby 
1980) 
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Figure 6  Biochemical pathway of glucuronidation 
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 1.4.6 Substrate characteristics 
Typically, glucuronidation involves compounds with nucleophilic functional groups of 
oxygen, nitrogen, sulfur, or carbon (Miners and Mackenzie 1991; Kroemer and Klotz 1992). The 
most common glucuronides are O-linked ethers from aliphatic alcohols and phenols or O-linked 
esters from carboxylic acid compounds. Although phase I metabolism often precedes 
glucuronidation, many compounds that contain functional groups such as hydroxyl, carboxy, 
amino or thiol, are directly conjugated without prior oxidation. (Sakaguchi, Green et al. 2004).  
Some common examples of drugs undergoing direct glucuronidation include morphine (Oguri, 
Ida et al. 1970; Yeh, Gorodetzky et al. 1977), acetaminophen, epirubicin (Weenen, van Maanen 
et al. 1984), ezetimibe (Ghosal, Hapangama et al. 2004), oxazepam (Sonne 1993), and valproic 
acid (Chapman, Keane et al. 1982). The four major chemical classes of compounds that undergo 
glucuronidation are shown in Figure 7. 
Glucuronidation renders the compounds more hydrophilic, facilitating their excretion in 
bile or urine. In most cases, glucuronide conjugates are inactive. However, some exceptions have 
been documented. Morphine-6-O-glucuronide has been shown to be a more potent analgesic than 
morphine. Some carboxylic acid drugs such as valproic acid form acyl glucuronides that form 
protein adducts,  which could result in carcinogenesis (Smith, Hasegawa et al. 1985; Williams, 
Worrall et al. 1992).  Similarly, adverse drug events including nephritis and acute renal failure, 
associated with nonsteroidal drugs of the aryl-alkyl class have been postulated to be due to the 
electrophilic interactions of the acyl glucuronides with the sulfhydryl and hydroxyl groups of cell 
macromolecules (Spahn-Langguth and Benet 1992). 
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Figure 7 Four classes of glucuronide metabolites.  
(The arrows indicate the position where glucuronidation occurs on the molecule) 
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The lack of substrate specificity exhibited by members of UGT families has been attributed 
to the characteristics of the substrate such as orientation of the groups and size of the chemical 
compound. Small and hydrophobic molecules are often glucuronidated by multiple UGTs (Lin 
and Wong 2002). Therefore, classification of the UGTs based on substrate specificity is limited. 
(Tephly and Burchell 1990) (Burchell 2003) In general, UGT1A enzymes conjugate a wider 
range of xenobiotics while UGT2B conjugate a substantial number of endogenous compounds 
(Radominska-Pandya, Little et al. 2001; McLean, Brandon et al. 2003).  UGT1A6 is known to 
preferentially conjugate planar phenols while UGT1A9 conjugates bulky phenols (Tukey and 
Strassburg 2000). Isoforms in the UGT2 family metabolize a variety of endogenous steroid 
compounds (Coffman, King et al. 1998).  Some isoforms do exhibit some substrate specificity. 
For example, UGT1A1 and UGT2B7 are primarily responsible for the glucuronidation of 
bilirubin and morphine, respectively (Coffman, Rios et al. 1997; Mackenzie, Miners et al. 2000).  
1.4.7 Factors regulating expression 
UGT enzyme expression in humans has been extensively studied and factors that determine 
levels of expression in the liver and extrahepatic tissues are beginning to be elucidated.  These 
factors include age, diet, ethnicity, disease states, drug interactions, genetic polymorphisms and 
hormones (de Wildt, Kearns et al. 1999).  Genetic polymorphisms have been reported for UGTs 
1A1, 1A6, 1A7, 1A8, 2B7 and 2B15 (de Wildt, Kearns et al. 1999; Bhasker, McKinnon et al. 
2000; Guillemette, Millikan et al. 2000; Tukey and Strassburg 2000; Huang, Galijatovic et al. 
2002; Miners, McKinnon et al. 2002). Genetic polymorphisms in UGT1A1 lead to either inactive 
proteins or partially active proteins causing two familial congenital hyperbilirubinemia 
syndromes. The severe form of the syndrome is commonly known as Crigler-Najjar syndrome 
and a mild form is known as Gilbert’s disease. The syndrome is characterized by elevated levels 
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of bilirubin, a breakdown product of heme. Recently, UGT1A1 promoter polymorphism was 
found to be associated with differences in SN-38 glucuronidation, indicating that genetic 
polymorphisms in UGT genes can alter pharmacokinetics of drugs and therefore alter their 
pharmacological effects and toxicities.  
The mechanism of induction of UGT1A1 by xenobiotics is thought to be via activation of 
the orphan nuclear receptors constitutive androstane receptor (CAR) and Pregnane X receptor 
(PXR) (Sugatani, Kojima et al. 2001; Xie, Yeuh et al. 2003). Recently, UGT1A1 has been shown 
to be inducible by the aromatic hydrocarbon (Ah) receptor also (Yueh, Huang et al. 2003).  
1.5 ACETAMINOPHEN: A PROBE FOR GLUCURONIDATION 
The investigation of drug interactions can be facilitated by the use of phenotypic probes. 
For the probe approach to be successful, availability of selective substrates, inhibitors and 
inducers is essential. The broad substrate specificity is responsible for the lack of specific probe 
substrates, inhibitors and inducers. This has remained an obstacle in the phenotyping of UGT 
enzyme activity in humans. With increasing interest in phase II drug metabolism, some 
compounds have been identified as selective substrates for in vitro testing and to measure 
activity in vivo. For example serotonin in in vitro studies has been identified as a selective 
substrate for UGT1A6, and morphine is believed to be metabolized in vivo exclusively by 
UGT2B7. Some substrates commonly used as probes for specific UGT enzymes are highlighted 
in table 2. Historically, acetaminophen has been the suggested in vivo probe substrate to measure 
UGT1A6 activity (Bock, Forster et al. 1993; Burchell, Brierley et al. 1995; Court and Greenblatt 
2000; King, Rios et al. 2000). Further, comparison of acetaminophen pharmacokinetics in cats, 
an animal species known to be deficient in UGT1A6 activity, and other species such as dogs and 
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humans suggests that UGT1A6 is the major enzyme catalyzing acetaminophen glucuronidation 
at therapeutic concentrations. However, recent studies have suggested that UGT1A9 to a large 
extent and UGT1A1 to a lesser extent contribute to acetaminophen glucuronidation (Court, Duan 
et al. 2001).  UGT1A6 as well as UGT1A9 are expressed in a wide range of tissues including 
liver, intestine, lung, kidney and brain (Sutherland, Ebner et al. 1993; King, Rios et al. 2000) 
(Tukey and Strassburg 2000). The UGT1A6 gene is highly polymorphic, and variability in 
UGT1A6 activity in the liver has been attributed to three common single nucleotide 
polymorphisms (cSNPs), in the coding region as shown in Figure 8.  Polymorphic expression 
and variability in UGT1A9 activity has also been reported. Several genetic polymorphisms have 
been identified, four in the coding region, Cys3Tyr, Met33Thy, Tyr242X, Asp256Asn, that lead 
to partial or complete inactivation of the protein (Jinno, Saeki et al. 2003; Villeneuve, Girard et 
al. 2003; Girard, Court et al. 2004).  
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Table 3 Partial list of substrates, inducers and inhibitors of UGT isoforms 
Substrates 
 
Inducers Inhibitors Isoform 
Endogenous 
 
Drugs Dietary 
compounds 
  
 
UGT1A1 
 
Bilirubin 
Catechols 
Thyroid 
hormones 
 
4-MU 
Estradiol 
Ezetimibe 
Etoposide 
SN-38 
 
 
Chrysin 
Apigenin 
Fisetin 
Genistein 
Narigenin 
Galagin 
Alizarin 
Emodin 
 
 
Phenobarbital 
Chrysin 
 
Probenecid 
UGT1A3 Catechol Clozapine 
Amitriptyline 
Apigenin 
Fisetin 
Genistein 
Naringenin 
Galagin 
 
  
UGT1A4 Pregnanediol Posaconazole 
Imipramine 
Tamoxifen 
Promethazine 
 
Menthol 
Borneol 
Carveol 
Carbamazepine 
Phenytoin 
Probenecid 
UGT1A6 Serotonin APAP 
4-MU 
Valproic acid 
 
Eugenol 
Β-Naphthol 
Phenobarbital 
Cruciferous 
vegetables 
Probenecid 
Diclofenac 
UGT1A9 Thyroid 
hormones 
Oestrogens 
APAP 
Propofol 
4-MU 
MPA 
 R-Oxazepam 
Almokalant 
Valproic acid 
 
Fisetin 
Naringenin 
Galagin 
Alizarin 
Emodin 
 
Cruciferous 
vegetables, 
smoking 
Probenecid 
UGT2B7 Bile acids 
Androsterone 
Catechol 
Retinoids 
Morphine 
Lorazepam 
Diclofenac 
AZT 
Rofecoxib 
R-Oxazepam 
Almokalant 
Valproic acid 
Menthol Cruciferous 
vegetables 
Valproic 
acid 
Substrates often used as probes are in bold 
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Figure 8  Acetaminophen glucuronidation 
 
 
 
 
 
Figure 9   UGT1A6 gene  
Figure showing the three coding polymorphism (Ref: Nagar. S et. al. 
Pharmacogenetics 2004, 14: 487-499) 
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1.6 SUMMARY AND OBJECTIVES OF RESEARCH  
Valerian is classified as “generally recognized as safe” by the Food and Drug 
Administration.  In spite of being one of the most popular herbs on the market, systematic 
pharmacokinetic studies investigating interactions between valerian and conventional 
medications are limited. Although a pharmacodynamic interaction has been suggested with 
barbiturates, no clinical study has been performed to confirm this interaction. Clearly, studies to 
investigate the interaction potential of valerian with conventional medications are warranted.  
 
Preliminary experiments in our laboratory indicated that alcoholic extracts of valerian 
inhibited acetaminophen glucuronidation to a greater extent compared to valerenic acid alone. 
The first hypothesis based on these results was that multiple constituents of valerian extracts 
contributed to the inhibition of UGT enzymes in human liver microsomes. The first goal of this 
dissertation was to isolate and identify the major compounds in valerian extracts that inhibit 
glucuronidation. The novel bioassay-guided approach adopted to achieve this goal is described in 
Chapter 3. The second hypothesis, also based on the results of the microsomal experiments, was 
that administration of valerian will inhibit UGT enzymes in vivo in humans. This hypothesis was 
tested in a two-phase clinical study using acetaminophen as the phenotypic probe substrate in 
healthy human volunteers. The methods and results of the study are described in Chapter 4. In 
the first phase, acetaminophen was administered alone. Subjects were asked to self administer 
valerian at bed time for a week and return for the second phase, when acetaminophen was 
administered in combination with valerian.  Blood and urine samples were obtained to measure 
acetaminophen and the glucuronide concentrations. The assay developed and validated to 
measure acetaminophen and acetaminophen glucuronide in human plasma is described in 
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Chapter 2. The pharmacokinetic parameters were calculated for the two phases and compared. 
The results showed that the administration of valerian did not significantly alter the 
pharmacokinetics of acetaminophen. The fact that the only significant observation was an 
increase in Cmax and reduction in tmax indicate that valerian increased the rate of absorption of 
acetaminophen but not the extent of absorption. These results were the basis of the third 
hypothesis, that valerian extracts induce UGT enzymes on chronic treatment and inhibit the 
enzymes on acute exposure, resulting in opposing effects that yield no net change in enzyme 
activity. As human liver microsomes lack cellular integrity, they cannot be used to evaluate 
enzyme induction.  Hence, experiments were performed in human hepatocyte culture system to 
evaluate potential inductive effects. The design and results of these experiments is described in 
Chapter 5.  
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2.0  DEVELOPMENT AND VALIDATION OF A HIGH-PERFORMANCE 
LIQUID CHROMATOGRAPHY ASSAY FOR THE SIMULTANEOUS 
DETERMINATION OF ACETAMINOPHEN ACETAMINOPHEN 
GLUCURONIDE AND ACETAMINOPHEN SULFATE IN HUMAN 
PLASMA   
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2.1 INTRODUCTION 
Acetaminophen (N-acetyl-p-aminophenol; APAP) was first synthesized in 1877 and was 
introduced into clinical practice as an analgesic in 1893 (Clissold 1986). Acetaminophen is a 
metabolite of phenacetin, which was developed as an analgesic drug in 1886 (Haas 1983). 
Phenacetin was withdrawn from the market after several reports of nephritis. Acetaminophen is 
now widely used alone and in combination with other drugs as an analgesic and antipyretic agent 
(Beaver 1981; Bannwarth, Latreyte et al. 1997; Renkes and Trechot 1998). The mechanism 
underlying the analgesic effect of acetaminophen is believed to be through the inhibition of 
peripheral cyclo-oxygenases (COX), central COX inhibition or indirect interaction with the 
serotonergic system (Brune 1988).  
Acetaminophen pharmacokinetics has been extensively studied and is well characterized in 
humans. Modest inter-individual variability is observed in the formation of acetaminophen 
glucuronide as indicated by the seven fold variability in human liver microsomes (Fisher, 
Vandenbranden et al. 2000). After oral administration, acetaminophen is rapidly absorbed from 
the small intestine and peak plasma concentrations (Cmax) are attained 30–90 minutes post 
administration (Clements, Heading et al. 1978; Sahajwalla and Ayres 1991). The half life of 
acetaminophen is approximately 3 hours (Levy and Regardh 1971). In humans, acetaminophen is 
extensively metabolized into glucuronide (60%) and sulfate (35%) conjugates and only 
approximately 2% is excreted unchanged in the urine (Nelson 1982). About 3% of the drug is 
oxidized via the hepatic cytochrome P450 (CYP) system to a chemically reactive intermediate 
that combines with liver glutathione to form a non- toxic compound (Figure 10).    
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Figure 10 Pathways of biotransformation of acetaminophen in humans 
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 Acetaminophen is not highly bound to plasma proteins at therapeutic concentrations and 
protein binding ranges from less than 5% to 24% (Milligan, Morris et al. 1994) (Rumack 2002). 
Because acetaminophen undergoes extensive glucuronidation, it is used as a probe substrate to 
measure UDP-glucuronosyltransferase (UGT) enzyme activity (Greenblatt, Abernethy et al. 
1983; Studenberg and Brouwer 1993).  UGT1A6 and UGT1A9 have been identified as the major 
isozymes catalyzing the formation of the glucuronide at low and therapeutic concentrations, 
respectively (Bock, Forster et al. 1993). UGT1A1 has also been shown to be involved in 
acetaminophen metabolism at high (toxic) concentrations (Court, Duan et al. 2001).  
Acetaminophen and acetaminophen glucuronide concentrations have been measured in 
biological fluids (e.g., plasma, urine and saliva), for a variety of reasons including determination 
of dose related pharmacokinetics, drug interactions, effect of disease conditions and forensic 
purposes. Several assays have been published for the determination of acetaminophen along with 
the glucuronide, sulfate, cysteine and mercapturate metabolites. Older papers have used simple 
techniques such as thin-layer chromatography (Andrews, Bond et al. 1976). Although the 
technique is simple, it would take an enormous amount of time when applied to multiple plasma 
samples obtained from a clinical pharmacokinetic study. Recently, several HPLC methods have 
been described. However, most methods were unable to adequately separate acetaminophen and 
its glucuronide (al-Obaidy, McKiernan et al. 1996; Brunner and Bai 1999). Some assays did not 
use an internal standard or lacked details on reproducibility (Riggin, Schmidt et al. 1975; Wong, 
Solomonraj et al. 1976). Disadvantages of some of the other methods include a high lower limit 
of detection, complex sample preparation or long run times (Wong, Solomonraj et al. 1976; Blair 
and Rumack 1977; Howie, Adriaenssens et al. 1977; Lee, Ti et al. 1996; Brunner and Bai 1999).  
 31 
As part of a study to investigate the effect of valerian extracts on acetaminophen glucuronidation 
in healthy human volunteers (Chapter 4), an HPLC method with UV detection was developed to 
measure acetaminophen and its glucuronide and sulfate metabolites in plasma. The dose of 
acetaminophen administered in the study was 500 mg and the estimated peak acetaminophen 
glucuronide concentrations from this dose ranges from 6-12 µg/ml. Earlier, an HPLC assay to 
measure acetaminophen and acetaminophen glucuronide in samples of human liver microsomes 
was developed and validated in our laboratory (Alkharfy and Frye 2001). This assay was 
modified for use with plasma and to increase the sensitivity.  
2.2 EXPERIMENTAL 
2.2.1 Reagents and chemicals 
APAP, APAPG, APAPS and paraxanthine (1, 7–dimethylxanthine) were purchased from 
Sigma (St. Louis, MO, USA). Potassium phosphate, ethanol, and methanol were obtained from 
Fisher Scientific (Fair Lawn, NJ, USA). Acetic acid was purchased from Aldrich Chemical 
Company, Inc. (Milwaukee, WI, USA). All chemicals utilized were of the highest purity 
available for analytical research. Written informed consent was obtained from all the subjects 
and the protocol was approved by University of Pittsburgh Institutional Review Board (Protocol 
# 0312032). Blank human plasma was purchased from the Central Blood Bank of Pittsburgh 
(Pittsburgh, PA, USA). Plasma was separated from blood samples of the subjects in the study by 
centrifugation at 4oC. Plasma aliquots were stored at -80˚C until analyzed. 
2.2.2 Instrumentation  
The HPLC system consisted of Waters model 717 autosampler, model 501 HPLC pump 
and model 486 ultraviolet detector set at 254 nm (Waters corp., Milford, MA, USA). The mobile 
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phase consisted of 10% methanol, 1% acetic acid in 0.1M phosphate buffer. The mobile phase 
was degassed under vacuum and filtered prior to use. The mobile phase was delivered at a flow 
rate of 1 ml/min through a Waters Symmetry® C18 5µ, 3.9 × 150 mm column. Signal output 
was captured using Empower™ software (Waters Corp., Milford, MA, USA). The run time was 
12 minutes.  
2.2.3 Standard preparation 
Stock solutions of APAP, APAPG (1 mg/ml) and APAPS were prepared in water and 
stored at -80˚C. Blank plasma was spiked with appropriate volumes of APAP stock to obtain 
concentrations of 0.5, 1, 2.5, 5, 10 and 20 µg/ml, which are concentrations that span the range 
expected for an acetaminophen 500 mg dose. For APAPG and APAPS, blank plasma was spiked 
to obtain final concentrations of 1, 2, 5, 10, 20 and 30 µg/ml. Aliquots (1 mL) were prepared and 
stored at -80˚C. Quality control standards were prepared in blank plasma at concentrations of 
1.5, 7.5 , 15 µg/ml for APAP and 4, 12, 25 µg/ml for APAPG and APAPS.  
2.2.4 Sample preparation 
Aliquots of plasma (250 µL) were placed in microcentrifuge tubes. Plasma samples were 
deproteinized by addition of perchloric acid (25 µL, 6 %) containing 25 µg paraxanthine 
(internal standard). Samples were vortex-mixed briefly and then centrifuged at 14,000 g for 10 
minutes. The supernatant was transferred to HPLC vials and a 150-µL aliquot was injected onto 
the HPLC system for analysis. 
2.2.5 Calibration and linearity 
Calibration curves were obtained daily for three days using six non-zero standard 
concentrations of APAP APAPG and APAPS in human plasma. Calibration curves were 
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constructed with triplicates of lowest concentration (0.5 µg/ml for APAP and 1 µg/ml for 
APAPG and APAPS) and duplicates of the higher concentrations. For each curve, the APAP to 
IS, APAPG to IS and APAPS to IS peak height ratios were calculated and plotted against the 
nominal APAP APAPG and APAPS concentrations. Calibration curves for APAP APAPG and 
APAPS were generated by weighted (1/y2) linear regression analysis. 
2.2.6 Precision and accuracy 
The precision and accuracy of the assay was determined using quality control (QC) 
samples of a low concentration, a middle concentration, and a high concentration for APAP 
APAPG and APAPS. Intraday variation of the assay was assessed by injecting replicate samples 
of QC (n=12) at each concentration for APAP, APAPG and APAPS on the same day. Inter-day 
variation was assessed by injecting replicate QC (n=24) samples on Day 1 (n = 12), Day 2 (n = 
6), and Day 3 (n = 6) for at each concentration for each compound. Mean, standard deviation and 
relative standard deviation (RSD) were calculated from the QC values and used in the estimation 
of intra- and inter-day precision. Accuracy (bias) is expressed as the percent deviation between 
the mean concentrations relative to the nominal concentration. 
2.2.7 Selectivity and Stability 
Selectivity was evaluated by processing and analyzing blank plasma obtained from six 
different sources. Blank plasma samples were processed in duplicate and compared to plasma 
spiked with the lowest (0.5µg/ml) APAP, (1 µg/ml) APAPG and (1 µg/ml) APAPS standards. 
Sample carryover was evaluated by inserting vials containing blank mobile phase in various 
positions throughout a validation run. Stability was not studied for this assay since several 
authors have reported that APAP, APAPG and APAPS are stable in plasma for at least 3 months 
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when stored at -80°C (Wilson, Slattery et al. 1982; Brunner and Bai 1999). The limit of 
quantitation (LOQ) was defined as the lowest standard value having a signal to noise (S:N) ratio 
of at least 10:1 and acceptable precision and accuracy (i.e., within 15%). The limit of detection 
(LOD) was defined as the smallest detectable peak having a S:N ratio of at least 3:1. 
2.3 RESULTS 
2.3.1 Chromatographic separation 
Representative chromatograms for plasma samples are shown in Figure 11.  The described 
method yielded sharp and well resolved peaks for APAP, APAPG, APAPS and the IS 
paraxanthine. There was no interference from endogenous compounds with any of the peaks. 
The figure depicts a blank plasma sample (no IS), plasma spiked with APAPG, APAPS, APAP 
and the IS, and a plasma sample from a subject at obtained two hours after acetaminophen 
administration.  The retention times for APAPG, APAPS, APAP and IS were 3.5, 5.8, 6.7 and 
9.8 minutes, respectively. The total time of analysis is 12 minutes.  
2.3.2 Precision, Linearity, and Accuracy 
A good linear relationship between the peak height ratio and concentration was observed 
over the entire range for APAP, APAPG and APAPS.  Linear calibration curves were obtained 
for APAP over the concentration range of 0.5 to 20 µg/ml and for APAPG and APAPS over the 
range of 1.0 to 30 µg/ml. The mean correlation coefficient (r2) for the standard curves was 
> 0.998.  Response remained linear at all concentrations with no saturation of signal. Intra- and 
inter-day precision for APAP, APAPG and APAPS were within ± 3.6 %, ± 7.06 %, and ±8.1 
respectively and the accuracy was within 1.1% 2.7% and 2.2 %for APAP, APAPG and APAPS 
respectively (Table 4). 
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Figure 11 Representative chromatograms of acetaminophen, acetaminophen 
glucuronide, acetaminophen sulfate and paraxanthine in plasma 
Panel A : blank plasma (----) and plasma spiked (⎯ )  at LOQ concentration of APAP 
(0.5µg/ml) and APAPG(1µg/ml) (offset = 10 mV); (B) acetaminophen, acetaminophen 
glucuronide and acetaminophen sulfate in plasma at 2 hours after single 500 mg dose of 
acetaminophen ; Peaks (1) APAPG  (2) APAPS (3) APAP and (4) I.S. 
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Table 4 Inter-day variability precision and accuracy of APAP APAPG and APAPS in 
calibration standards  
Concentration (µg/ml)  
Standards Observed 
(mean ± SD) 
 
% RSD 
 
% Bias 
APAP 0.5    0.48 ± 0.02 4.06 -3.62 
 1.0    0.99 ± 0.03 3.08 -1.08 
 2.5    2.51 ± 0.02 0.66 0.59 
 5.0   4.98 ± 0.09 1.83 -0.42 
 10.0 10.11 ± 0.13 1.24 1.15 
 20.0 19.96 ± 0.13 0.65 -0.22 
  
APAPG 1 
 
1.04 ± 0.06 6.03  3.55  
 2 
 
1.98 ± 0.05 2.53 -1.02 
 5 
 
5.01 ± 0.13 2.58   0.17 
 10 
 
10.12 ±0.18 1.79   1.21 
 20 
 
19.79 ± 0.20 1.03 -1.01 
 30 
 
30.10 ±0.15 0.49   0.35 
 
 
APAPS 1 
 
1.01 ± 0.07 7.1  1.2  
 2 
 
1.99 ± 0.03 1.95 -1.1 
 5 
 
4.99 ± 0.08 1.61 -1.0 
 10 
 
9.98 ± 0.21 2.08 -2.1 
 20 
 
19.96 ± 0.13 0.67 - 4.1 
 
 30 
 
30.03 ± 0.12 0.40   6.0 
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Table 5  Intra day and inter day variability precision and accuracy of APAP, APAPG 
and APAPS in plasma 
   
Intra-day (n= 12) 
 
Inter-day  (n= 24) 
 
 
QC Observed % RSD % Bias Observed % RSD % Bias 
 
 
APAP 
 
1.5 
 
 1.5 ± 0.1 
  
 3.6 
 
-0.4 
 
 1.5 ± 0.1 
 
1.7 
 
-0.2 
 7.5  7.6 ± 0.2  2.3  1.1  7.5 ± 0.1 1.9  0.1 
 15 15.0 ± 0.1  0.8  0.3 15.0 ± 0.1 0.7  0.3 
        
APAPG 4  3.9 ± 0.3  7.06 -2.2  3.9 ± 0.2 5.6 -1.5 
 12 11.7 ± 0.6  5.3 -2.7 11.8 ± 0.3 2.4 -1.5 
 25 25.2 ± 0.5  1.9 0.8 25.1 ± 0.2 1.0   0.2 
        
APAPS 4  4.1 ± 0.2  6.2  1.1  4.1 ± 0.3  8.1  2.2 
 12 12.1 ± 0.2  1.7  1.8 12.2 ± 0.4  2.9  2.1 
 25 24.9 ± 0.3  1.2 -1.0 25.2 ± 0.2  0.9  1.8 
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2.4 DISCUSSION 
We report a simple and rapid HPLC method to separate and quantify acetaminophen and its 
glucuronide metabolite in plasma samples. This method does not require expensive or time 
consuming solid phase extraction techniques. Sample preparation was a simple perchloric acid 
deproteinization without requirement of further purification.  The run time required for this 
method is short, minimizing the overall time required for assay. Since acetaminophen has been 
used for several years, a number of assays have been described to measure acetaminophen and its 
metabolites in various body fluids (Wagner, Wagner et al.). A 500 mg dose of acetaminophen 
was used in our study.  In order to accurately estimate the pharmacokinetic parameters, a very 
sensitive reproducible analytical method was required.  The present method is a simple, rapid 
assay with good resolution of acetaminophen and its glucuronide and sulfate metabolites. This 
method was used to support the pharmacokinetic study described in Chapter 4.  
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3.0  BIOASSAY GUIDED FRACTIONATION FOR ISOLATION AND 
IDENTIFICATION OF COMPOUNDS IN VALERIAN EXTRACTS THAT 
INHIBIT ACETAMINOPHEN GLUCURONIDATION 
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3.1 INTRODUCTION  
3.1.1 Valerian  
3.1.1.1 Taxonomy and Morphology  
Valerian is a member of the family Valereianceae of the genus Valeriana L., which 
comprises of 200 species worldwide (Bailey, Bailey et al. 1976) (Hickey and King 1988). 
Valerian is indigenous to most parts of Europe and northern Asia (Flèuckiger and Hanbury 1879; 
Clapham, Tutin et al. 1987). Valerian is a perennial rhizomatous herb growing up to 5 feet and 
giving rise to new plants from horizontal runners. The most commonly used species is Valeriana 
officinalis L. Valeriana officinalis has pinnately divided basal leaves, stem leaves with 11-21 
leaflets, a sparsely pubescent rachis and abaxial surfaces. The grooved stalk is usually simple 
with dentate-serrated leaves and with small fragrant pink or white flowers. The inflorescence is a 
terminal compound cyme.  The genus exhibits polyploidy leading to diploid, tetraploid (central 
European) and octaploid (British origin) forms (Bos, Woerdenbag et al. 1994; Upton 1999; 
Wills, Bone et al. 2000).  
The rhizomes, roots and stolons are used for medicinal purposes (Bos, Woerdenbag et al. 
1994; Bos, Woerdenbag et al. 1996). When dried, the rhizomes are up to 50 mm long and up to 
30 mm in diameter. The rhizome contains numerous thick, brown rootlets. The root is 
longitudinally wrinkled and approximately 100 mm long and 1-3 mm in diameter, almost 
cylindrical and almost the same color as the rhizome. The stolons are 20-50 mm long, pale 
yellowish-grey in color and possess prominent nodes separated by longitudinally striated 
internodes. The rootlets contain most of the essential oil.  They are brittle and break in short, 
horny fractures. 
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3.1.1.2 Etymology of name  
The origin of the name Valerian is uncertain, although the ancient Greek physicians Pliny 
and Dioscorides have used the term “Valeriane” to refer to V. tuberose (Pickering 1879). Some 
authors believed that the name was derived from Latin, in which valere means health or well-
being and some claim that ancient Romans named it in honor of Valerius, the physician who 
used it first in medicine (Paxton and Hereman Samuel. 1868; Jaeger 1955). It seems to have first 
appeared in literature between the 9th and 10th centuries. Valerian has also been known as Nard 
and believed to originate from the Sanskrti nalada or Hebrew nerd (Kindåi, Levey et al. 1966). 
Valerian has been referred to as phu or fu as early as 1515, a name usually interpreted as an 
expression of disgust associated with the strong smell of long-dried valerian root (Thompson 
1830; Flèuckiger and Hanbury 1879; Pickering 1879; Dioscorides, Goodyer et al. 1959). 
Valerian is known as baldrian in Germany and valeriane in France. 
3.1.1.3 History of Valerian Use 
The use of valerian in medicine dates back to the period of Hippocrates (460- 370 B.C.), 
when the ancient Greeks used valerian for its bitter and aromatic properties (Fuchs 1895-1908). 
The first century Greek physician Dioscorides and his contemporaries, Pliny (23-79 A.D.) and 
Galen (131-201 A.D.), are said to have recommended valerian for a myriad of disorders 
including heart palpitations, digestive problems, epilepsy, pain and urinary tract infections 
(LaFrance, Lauterbach et al. 2000). The Greeks are reported to have used valerian as an 
emmengogue, antiperspirant and antidote for poisons (Dioscorides, Goodyer et al. 1959). 
Historically, the Greek and Roman physicians mainly used valerian as a diuretic, analgesic and 
antispasmodic agent. In the Bible, valerian is mentioned as a flavoring agent for food and as a 
healing oil in a soothing salve for the head (Ainslie 1984; Sanyal 1984). From the 8th to the 13th 
centuries, valerian was a popular medicinal agent in the Arabian school, where it was 
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recommended to cure pustules of the mouth, to protect the gums from heat, to cure insanity and 
to strengthen breathing. In the 16th Century, the Italian botanist Fabius Columna reported that he 
was cured of epilepsy by valerian (Upton 2001). In medieval times, Valerian was used as a 
panacea and has been referred to as all heal. Valerian was regarded as the best treatment for 
epilepsy in the 18th and 19th centuries (Eadie 2004). During the 200-year period from 1733-
1936, valerian was one of the six most prescribed medicines in European and American 
medicine (Hobbs 1990). It was in this period that valerian was established primarily as a nervine 
agent and since then, valerian has been used as a sedative and anxiolytic. Valerian was official in 
British pharmacopoeia in 1867, in the US pharmacopoeia from 1820 -1936 and in the US 
National Formulary until 1946 (Hobbs 1989). Valerian is currently listed under monographs for 
dietary supplements in a separate section of the USP. In 1967 it was official in the 
pharmacopoeias of Austria, Belgium, Brazil, Chile, Czechoslovakia, France, Germany, Hungary, 
Yugoslavia, Romania, Russia, Spain and Switzerland (Hobbs 1993). V. officinalis is included in 
the European Pharmacopoeia and was included in German commission E monographs since 
1985 as a sleep aid. V. wallichi is official in the Indian Pharmacopoeia.  In the ancient Indian 
medicine system, Ayurveda, V. jatamamsi is used as tonic, stimulant, antispasmodic, diuretic and 
as antidote for poisons (India. Dept. of Indian Systems of Medicine & Homoeopathy. 1999). In 
traditional Chinese medicine, V. jatamamsi has been known as an odorant. In the Chinese 
Pharmacopoeia called Pen Ts’ao, valerian is cited as being used as a deodorant, carminative, 
headache reliever, and treatment of malaria(Shin-Chen 1578; Perry 1980).Table 6 summarizes 
the uses of valerian over the centuries and its listing in official and unofficial compendia.  
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Table 6 Official and unofficial compendia 
Herbal/ Compendia                                     Date              Uses 
Pliny’s Natural History 60  A.D. Sedative 
Galen & Pedanius Dioscorides’s  
De Materia Medica 
160 A.D.  Insomnia, antispasmodic , astringent, 
antiperspirant, digestive & urinary tract disorders 
Leonhart Fuchs’  The Great Herbal 1542 For colic, stomach disorders 
Maththiolus  1544 Diuretic, anodyne, emmenagogic, carminative for 
coughs, asthma 
Dodoens 1554 Gargle for throat infections 
Turner  1568 Perfume 
Phytobasanos of Columna 1592 Anticonvulsant 
Gerard 1597 Diuretic, treatment of jaundice, cramps, 
convulsions ulcers of mouth and gum sores 
Parkinson 1640 To treat coughs, plague, short-windedness 
Culpeper’s  Complete Herbal 1649 Nervousness, trembling, headaches, and heart 
palpitations 
James Alleyne's  A New English 
Dispensatory  
1733 Nervousness, hysteria 
R. James'  Pharmacopoeia Universalis  1745 Sudorific, diuretic, poor sight, asthma, cough, 
liver stagnancy, jaundice, epilepsy 
Andrew Duncan's  Edingurgh New 
Dispensatory  
1791 Nervous system debility, epilepsy 
William Cullen's  A Treatise of the 
Materia Medica  
1802 Antispasmodic, sedative for hysteria 
James Thatcher's  The American New 
Dispensatory  
1813 Sedative, antispasmodic 
Coxe’s  American Dispensatory 1830 Pain reliever, comforts stomach, induces sleep 
London Dispensatory 1833 Hypochondriasis, flavoring agent for food 
Jonathan Pereira's  The Elements of 
Materia Medica and Therapeutics   
1843 Nervine, antispasmodic 
Trousseau’s  Materia Medica 1880 “vapors” in women 
John Milton Scudder’s  
Specific Medications 
1903 Cerebral stimulant, analgesic, and sedative useful 
in nervous irritability 
King’s American Dispensatory 1898 Aromatic stimulant , rheumatism, hysteria, low 
grade fevers, as an aphrodisiac   
Ellingwood’s   Systematic Treatise on 
Materia Medica and Therapeutics  
1900 Nervine and sedative for the treatment of hysteria, 
epilepsy, and menopausal nervous anxiety 
Grieve’s 
 A Modern Herbal 
1931 Nervous overstrain, poor eye sight, insomnia, 
cardiac palpitations, cholera and as perfume 
Torald Sollmann's  
A Manual of Pharmacology 
1936 Antispasmodic, sedative 
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3.1.1.4 Chemical constituents  
The constituents of major interest due to their sedative activity are the essential oil, 
sesquiterpenoids and epoxy iridoid esters (valepotriates) (Houghton 1999; Upton 1999). Apart 
from the iridoids and terpenoids, valerian is also known to contain small quantities of alkaloids, 
lignans and flavonoids (Upton 1999; Schumacher, Scholle et al. 2002; Marder, Viola et al. 
2003). The primary constituents of Valeriana officinalis are summarized in Table 2. The roots 
and rhizomes are known to contain essential oils stored in the hypodermis. According to the 
European Pharmacopoeia, the crude drug, Valerianae radix contains not less than 0.5% (v/m) of 
essential oil(Bos, Woerdenbag et al. 1998).  Typically, the essential oil content in roots harvested 
within 2 years ranges from 0.9-2.1%. The main constituents of the essential oil are valerenone 
(10-21%), cryptofauronol (5-12%), valerenal (2-5%), valerianol (1-6%) and bornyl acetate (1-
3%). The total valerenic acid content (valerenic acid and acetoxy valerenic acid) of roots 
harvested within 2 years ranges from 0.1-0.9% and total valtrate content (valtrate and isovaltrate) 
ranges from 0.1-1.1%. During drying and storage, some valpotriates undergo hydrolysis and give 
rise to baldrinals (Dewick 2002). Structures of sesquiterpenoids, valepotriates and baldrinals are 
shown in Figure 12.   
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Table 7 Chemical constituents of Valeriana officinalis  
1.Essential oil (0.2-1%)  
• Monoterpenes 
(-)-Bornyl isovalerenate 
(-)-Bornyl isovalereneic acid 
 
 
• Sesquiterpenes 
Valerenic acid (0.1- 0.9%) 
2-Hydroxy valerenic acid 
2-Acetoxyvalerenic acid 
Valerenal (3-16%) 
Valerenone (0-18%)  
Valerenol 
Pacifigogiol (0.7-8.6%) 
2. Iridoids 
• Monoene-Valepotriates 
Didrovaletrate  
Isovaleroxyhydroxydidrovaltrate(10-20%)
• Diene-Valepotriates  
Valtrate ((80-90%) Ref(Stahl and Schild 
1971; Samuelsson 1992) 
Isovaltrate  
Acevaltarate 
 
• Valepotriate Hydrines 
• Desoxy monoene Valepotriates 
8, 11 Desoxididrovaltrate 
8,11 Desoxihomodidrovaltrate 
• Other Valepotrites 
Patrinoside 
Valechlorine 
Valerosidate 
• Breakdown products 
Baldrinal 
Homobaldrinal 
3. Alkaloids 
• Actinidine 
• Isovaleramide 
4.  Caffeic acid derivatives 
• Chologenic acid 
5. Lignans 
• 8-Hydroxypinoresinol 
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Figure 12 Structures of sesquiterpene derivatives and valepotriates in Valeriana officinalis 
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3.1.1.5 Cultivation and collection 
Valerian is cultivated in several European countries including Britain, Belgium, France 
and Germany (Upton 1999). Valerian is also cultivated in the United States in Vermont, New 
Hampshire, New York and in the Pacific Northwest (St. Hilaire 2003).  Harvest times vary 
geographically. The essential oil content varies with genotypes, harvest times, growing 
conditions, age of root, drying and extraction techniques. Essential oil content is reported to be 
higher in plants grown in higher elevations with dryer environment and in phosphate-rich soils.  
The essential oil content is higher in roots of one-year old plants compared to two year old 
plants. Valerenic acid content and valepotriate contents also follow the same pattern. Plants 
harvested in September are reported to have the maximum volatile oil content ranging from 1.2 
% to 2.1 % while valepotriates are at a maximum in plants harvested in February-March. Root 
materials are typically dried at 50˚C for 52 hours or at room temperature for 10 days. The 
valerenic acid content does not differ between the two drying methods. Volatile oil content of 
material collected in the Pacific Northwest ranges between 0.4% and 1.3% and material used for 
preparation of commercial products is required to contain at least 0.5% valerenic acid.  
3.1.2 Bioassay guided fractionation 
Plants have been a major source of medicinal compounds for the development of several 
pharmaceutical products. As natural products are often complex mixtures of chemical 
compounds, some of them lacking biological activity, isolation of the active compound is 
necessary for drug development. In the early 1950s, the strategy of bioassay-guided fractionation 
and isolation using chromatographic separation techniques revolutionized medicinal plant 
research. Bioassay-guided isolation is an integration of chemical separation of compounds in a 
mixture with biological testing (Figure 13). The first step in this process is testing an extract to 
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confirm its activity. The second step is a crude fractionation of the extract leading to separation 
of the compounds in the matrix and testing the crude fractions. Further fractionation is 
undertaken on the fractions that show biological activity, at a certain concentration threshold, 
while the inactive fractions are set aside or discarded. The process of fractionation and biological 
testing is repeated until pure compounds are obtained. The final step is structural identification of 
the pure compound. Although the bioactivity-guided fractionation methods are traditionally used 
in drug discovery, a similar approach is seldom adopted for drug metabolism studies, where 
either whole plant extracts or known constituents of medicinal plants are used. A well known 
example of studies performed with known constituents is hyperforin in St. Johns wort (Moore, 
Goodwin et al. 2000; Cantoni, Rozio et al. 2003). The bioassay guided approach was chosen for 
our studies since preliminary work in our laboratory comparing the effect of valerenic acid and 
the alcoholic extract of valerian on acetaminophen glucuronidation showed that the whole extract 
inhibited glucuronidation to a greater extent than valerenic acid alone. These results suggested 
that other compounds in the extract contributed to inhibition of acetaminophen glucuronidation.  
Being a systematic approach, this methodology precludes overlooking compounds that could be 
biologically active even if present in small quantities. The objective of the present study was 
isolation of compounds in ethanolic extracts of Valeriana officinalis capable of inhibiting 
acetaminophen glucuronidation by the bioassay guided approach.    
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Figure 13 General scheme for bioassay guided isolation  
(Adapted from Rimando et. al Journal of Agronomy 2001 93 (1), 16-20) 
     LLE- Liquid Liquid Extraction, SPE- Solid phase extraction 
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• EXPERIMENTAL 
3.1.3 Materials and Methods 
3.2.1.1 Plant material: 
Herbal products are commonly marketed in two forms: the powdered herb, and the 
powdered herbal extract, the latter being incorporated into a suitable dosage form and 
standardized to contain a specific percent of a designated marker compound. Valerenic acid has 
been established as the marker compound for valerian products. Valerian extracts are available in 
the form of liquid or powder. The plant material for the experiments described in this project is 
found in a commercial product. The product was composed of a soft gel capsule containing a 
liquid alcoholic extract along with excipients. The label claim of containing 0.8% valerenic acid 
was confirmed in our laboratory by HPLC. 
3.2.1.2 Chemicals 
Valerian capsules (250mg; PharmAssure, Phoenix, AZ, USA) were obtained from a local 
retail pharmacy. Pure valerenic acid was purchased from Indofine chemical company 
(Sommerville, NJ, USA). Acetaminophen, acetaminophen glucuronide, alamethicin, uridine 
diphospho-glucuronic acid (UDPGA) and magnesium chloride were purchased from Sigma (St. 
Louis, MO, USA). Petroleum ether, ethyl acetate, methylene chloride, methanol and ethanol 
were purchased from Fisher Scientific (Fair Lawn, NJ, USA). HPTLC plates (5 x 7.5 cm) coated 
with silica gel 60 with fluorescence indicator (Merck, Darmstadt, Germany) were purchased 
from EM Science Gibbstown, NJ, USA. 
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3.2.1.3  Bioassay 
The liver is the principal site of drug metabolism in the body and contains a wide 
spectrum of drug metabolizing enzymes. Therefore, in vitro studies on drug metabolism are 
usually performed using liver tissue. In vitro models of the liver commonly used to evaluate drug 
interactions are liver slices, hepatocytes, liver microsomes and cDNA-microsomes. Liver 
microsomes are advantageous as they are simple to use, can be preserved for long periods of 
time at -80°C and are relatively easy to prepare. This model system requires only a very small 
amount of compound in order to perform the tests. Therefore, liver microsomes were chosen as 
the model to evaluate the effect of the isolated fractions on UGT enzyme activity. 
Acetaminophen was used as the model substrate for determination of UGT activity as this drug is 
extensively glucuronidated. Incubations were performed as described by Alkharfy et. al 
(Alkharfy and Frye 2001).  Human liver microsomes (0.5 mg/ml final protein concentration) and 
alamethicin (30µg/mg protein) were pre-incubated on ice for 5 min. The active site of the UGTs 
is located in the lumen of the ER resulting in latency in site activity.  Alamethicin (an antifungal 
peptide) has been successfully used as a permeating agent to overcome the latency of UGT 
enzymes in previous studies in our laboratory. The incubation mixture consisted of magnesium 
chloride (5 mM), and acetaminophen (10 mM) in a final incubation volume of 250µl. The 
reaction was started by adding 4 mM of UDPGA, incubating the samples at 37°C for 1 hour, and 
terminating the reaction by addition of 25µl of 6% perchloric acid containing 25µg paraxanthine 
(internal standard), followed by vortex-mixing and cooling on ice. The supernatant was isolated 
by centrifuging the samples at 2000 g  for 5 min. Acetaminophen glucuronide concentration in 
the microsomal incubates was determined by reverse phase HPLC, utilizing a symmetry C18 
column and a mobile phase composed of methanol, acetic acid and water (10:1:89, v/v/v), with 
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UV detection at 250nm.  Acetaminophen glucuronide formation was quantitated by comparing 
the peak height in the incubations to a standard curve containing known amounts of the 
metabolite in the range 0.1-25 nmol. The standard curve correlation coefficients (r2) were 0.99. 
The formation rate of acetaminophen glucuronide in the incubations was 2.2nmol/min/mg 
protein in our laboratory and was simlar to that reported in the literature (Fisher, Campanale et 
al. 2000). Incubations were performed in the presence of extracts and fractions obtained by 
partitioning and chromatographic procedures and compared with incubations performed with 
vehicle only as a control to determine the effect of the extracts/fractions on acetaminophen 
glucuronide formation. Bioactivity is expressed as percent control.  
3.2.1.4 Extraction and isolation 
Mild fractionation and chromatographic methods were adopted in order to prevent 
destruction or alteration of potentially bioactive compounds. A simple solvent pair partitioning 
method was used to remove the maximal amount of inactive compounds. Capsules (250mg, 
n=10) of valerian root extracts were crushed and extracted three times with 80% aqueous EtOH 
(50 mL). The extracts were combined, and concentrated to dryness under reduced pressure at 
40oC with a rotary evaporator. Approximately 1.2g of the crude extract was obtained from ten 
capsules, and this extract was stored at 4oC. This extract was subjected to liquid-liquid 
partitioning between H2O (50 mL) and CH2Cl2 (2 × 250 mL). These fractions were separately 
evaporated in vacuo at 45oC and evaluated for bioactivity.  The CH2Cl2 fraction showed strong 
inhibition potential of acetaminophen glucuronidation while the water fraction was inactive. The 
strongly active CH2Cl2 fraction (300 mg) was further partitioned between EtOAc and H2O. After 
removing the solvents under vacuum, the residues from each partitioning [CH2Cl2 (300 
mg)/water (800 mg); EtOAc (220mg)/H2O (58.4mg)] were screened for bioactivity. The 
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sequence of extractions is shown in Figure 14. The bioactive EtOAc residue (223 mg) was 
subjected to normal-phase open column chromatography (Silica gel (6 g), 70-230 mesh column 
A: 10 × 100 mm). The column was slurry packed in petrol (30-60oC)- CH2Cl2 (1:4). The sample 
was dissolved in the same solvent, added to the column, and elution initiated with the identical 
solvent. Elution proceeded via a gradient CH2Cl2-MeOH system (CH2Cl2; CH2Cl2-MeOH 
mixtures; MeOH) to afford 10 fractions (F001-F010). Fraction 3 (F003), eluting with 99:1 
CH2Cl2-MeOH, was bioactive and was obtained in substantial amounts (weight 22.3 mg) 
compared to the other fractions. Therefore, this fraction was further separated on a Si gel column 
(5g) (column B: 10 × 100 mm).  The column was slurry packed in CH2Cl2, the sample dissolved 
in CH2Cl2 (3 mL) and added to the column.  Elution proceeded via gradient mixtures of d-
CH2Cl2-MeOH 100 %, (99.5:0.5) (99:1), (98:2), and (97:3) to yield 5 fractions. Only two 
adjacent fractions showed bioactivity, and these two active fractions were combined, and further 
chromatographed in a similar manner on a third Si gel column (Column C: 10 x 100mm).  The 
combined fractions were dissolved in petrol-CH2Cl2 (1:4) and eluted with petrol- CH2Cl2 (1:4), 
CH2Cl2 and CH2Cl2-MeOH (19:1) to yield 3 fractions. Only fraction 1 was sufficiently bioactive 
and obtained in modest amounts.   
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 Figure 14  Scheme showing bioactivity - guided fractionation 
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3.2.1.5 Chemical Identification 
Fraction 1 (15.1mg) of column C eluted with petrol-CH2Cl2 (1:4) and was analyzed by 
high performance thin-layer chromatography on HPTLC plates.  Three µl volumes of sample 
solutions and standard (valerenic acid) were applied 6 mm apart and 8mm from the lower edge 
of the plates. Plates were subjected to the following visualization procedures: 
a) UV (254 nm and 366nm) 
b) Sprayed with anisaldehyde-sulfuric acid reagent and air dried.  
The plates were then placed in the oven at 120°C for 2 minutes (or until color of standard 
developed). 
Fractions were also analyzed by a gradient HPLC with diode array detection. Analyses 
were carried out on a µBondapack C18 column (Waters, Milford, MA) with a linear gradient 
elution of a mobile phase composed of  MeOH (eluent A) and 0.5% H3PO4 (eluent B) . The 
gradient elution was programmed as follows: A was ramped up from 45% linearly to 80% from 
0-40 min, then A maintained at 80% for another 20 min. After completion of the HPLC run, the 
column was washed with 100% MeOH for 5 min. The pump was programmed to return to initial 
conditions within 3 min. and equilibrated for 15 min. with the initial mobile phase for the next 
injection. The flow rate was constant at 1 ml/min. The photo-diode array (PDA) detector was set 
to scan from 200–250 nm. The wavelength selected for the target compounds was 215 nm 
(giving an average maximum absorbance for all the compounds).   
 
Fractions corresponding to peaks were collected from the HPLC and further 
characterization of the fractions were performed by gas chromatography–mass spectrometry 
(GC-MS) (Hewlett Packard 5890 Series II gas chromatograph coupled to Hewlett Packard 
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5989A MS engine) operating in the EI mode at 70 eV, equipped with an HP-5 MS capillary 
column (30 m x 0.25 mm, film thickness 0.25 µm). GC oven initial temperature was 60°C and 
programmed to 280°C at a rate of 3°C/min. The carrier gas was helium at a flow rate 1 mL/min.    
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• RESULTS 
3.1.4 Identification of isolated compounds  
The capsules of valerian (Valeriana officinalis) were crushed and extracted with 80% 
alcohol. The ethanol extract was concentrated under reduced pressure at 40oC to a viscous 
residue that was dissolved in dichloromethane and partitioned between water and 
dichloromethane. The activity, as defined by inhibition of acetaminophen glucuronide formation, 
was retained in the organic phase (dichloromethane), with the aqueous phase being devoid of any 
inhibitory activity. 
The dichloromethane extract was evaporated to a residue that was further partitioned 
between ethyl acetate and water.  The activity was once again principally retained in the organic 
layer (ethyl acetate) while the aqueous layer fraction was only marginally active (Figure 15).  
The ethyl acetate extract was subjected to various chromatographic techniques including 
adsorption column chromatography (Figure 17), high-performance thin-layer chromatography 
(HPTLC) (Figures 16 & 18), and high pressure liquid chromatography (HPLC). Gas 
chromatography-mass spectrometry (GC-MS) was utilized to analyze fractions collected from 
HPLC and to aid in the identification of the three major sesquiterpene compounds:  valerenic 
acid, acetoxyvalerenic acid and valerenal.   
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Figure 15  Effect of the valerian extracts on UGT activity 
Acetaminophen glucuronide formation measured in pooled human liver 
microsomes after co-incubation with valerian extracts.  Results are expressed as 
percent control. Data are means ± S.D. of duplicate values.  
 
 
 
 
Figure 16 Thin Layer chromatography of valerian extracts 
A: Valerenic acid standard, B: Dichloromethane extract, C: Ethyl acetate 
extract, D: Column C fraction1, E: Column C Fraction 2 
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Figure 17  Effect of each fraction obtained from column A on UGT activity 
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Figure 18  Thin layer chromatography of the corresponding column fractions 
  (fraction 10 not shown) 
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3.3.1.1 Valerenic acid (Compound 1) 
Compound 1 was visible as a dark blue band on the thin-layer chromatogram after 
staining with Anisaldehyde reagent (Rf 0.48; hexane-ethyl acetate-acetic acid, [13:7:0.1]).  The 
retention time for the acid compound by HPLC analysis (mobile phase - methanol: water: acetic 
acid [80:20:0.1, v/v/v]; Symmetry C18 column; UV detection at 230nm) was 5.5 minutes.  The 
GC retention time was 10.1 min. The mass spectrum showed a molecular ion peak at m/z 234 
(73%), with other significant fragment ions at m/z 161 (90%), 133 (73), 122 (75), 107 (88), 105 
(88), 93 (51), 91 (100), 79 (66), and 77 (52).  Compound 1 was identified as the sesquiterpene 
valerenic acid on the basis of a direct comparison (TLC Rf and color; HPLC and GC retention 
times; GC/EI/MS) with an authentic sample (Dalton Chemical Laboratories Inc., Ontario, 
Canada).  The mass spectrum is shown in the figure 19.  
Valerenic acid was first isolated from the roots of Valeriana officinalis in 1957 by A. 
Stoll and colleagues (A. Stoll 1957). The structure of this compound was first elucidated by a 
combination of spectrometric methods by G. Buchi and collegues(Buchi, Popper et al. 1960). 
Valerenic acid has subsequently been isolated from Valeriana officinalis as well as Liqidambar 
styraciflua(Tattje and Bos 1979; Culvenor, Edgar et al. 1986). In a recent study, dichloromethane 
and petrol extracts of valerian were screened for ligands of the melatonin, serotonin, 
benzodiazepine, glutamate, and GABA receptors, or serotonin transporter (Dietz, Mahady et al. 
2005).  Results indicated that these extracts exhibited significant binding at the 5-HT5a receptor.  
Valerenic acid and acetoxyvalerenic acid were identified as being present in the dichloromethane 
and petrol extracts, and is in agreement with our conclusions. 
In mice studies, the essential oil of valerian and the isolated components valerenal, 
valerenic acid, valeranone, and isoeugenyl isovalerate showed sedative and muscle relaxant 
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activity(Hendriks, Bos et al. 1985). Valerenal and valerenic acid were shown to be the most 
potent compounds, with valerenic acid causing a decrease in rotorod and traction performance in 
mice at an intra-peritoneal dose of 100 mg/kg. In addition, valerenic acid was observed to 
produce a dose-related increase in pentobarbital-induced sleep at both 50 and 100 mg/kg ip 
dosage. 
3.3.1.2 Acetoxyvalerenic acid (Compound 2) 
Compound 2 was visible as a dark bluish-purple band on the thin-layer chromatogram 
after staining with anisaldehyde reagent (Rf 0.28; hexane-ethyl acetate-acetic acid, [13:7:0.1]).  
The retention time for the compound acid by HPLC analysis (mobile phase - methanol: water: 
acetic acid [80:20:0.1]; Symmetry C18 column; UV detection at 230nm) was 3.2 minutes.  The 
GC retention time was 11.3 min. The mass spectrum exhibited important fragment ions at m/z 
232 (85%)(M-60)(M-CH3COOH), 187 (28), 159 (40), 145 (34), 131 (37), 120 (100), 105 (39), 
91 (27), and 43 (32).  The mass spectrum of this compound is shown in figure 20.  Compound 2 
was identified as the sesquiterpene acetoxyvalerenic acid on the basis of a direct comparison 
(TLC Rf and color; HPLC and GC retention times; GC/EI/MS) with an authentic sample (Dalton 
Chemical Laboratories Inc., Ontario, Canada).  In addition to valerenic acid, acetoxyvalerenic 
acid has been identified as a characteristic constituent of V. officinalis and its subspecies (Riedel, 
Hansel et al. 1982). Acetoxyvalerenic acid was first isolated  from the roots of Valeriana 
officinalis in 1960 and has subsequently been isolated from numerous Valeriana species spp. 
collina, sanbucifolia, and related taxa such as V. celtica, V. angustifolia, V.montana, V.phu, and 
V. tripteris (Buchi, Popper et al. 1960; Bos, Woerdenbag et al. 1997). 
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3.3.1.3 Valerenal (Compound 3)  
The third major compound was identified as valerenal based on the GC/EI/MS 
fragmentation pattern shown in figure 21. The identification was established by comparing the 
fragmentation pattern of Compound 3 with that of literature values (Bos, Hendriks et al. 
1986).The GC retention time of this compound was 6.8 min. Since a standard of this compound 
is not available, the Rf on thin layer chromatography was not determined.  The mass spectrum 
showed a molecular ion peak at m/z 218, with other significant fragment ions at m/z 203(51), 
189(26), 185(74), 175(82), 161(52), 148(23), 147(53), 145(29), 143(16), 135(15), 133(42), 
131(23), 129 (15), 128(15), 121(30), 119(41), 117(29), 115(28), 109(20), 108(18), 107(49), 
106(16), 105(74), 103(12, 95(24), 93(47), 91(100), 81(29), 79(57), 78(15), 77(56),  67(20), 
65(24), 55(39), and 53(25). The spectrum is shown in figure 19.   
Valerenal has been isolated from V. Officinalis and identified in previous studies(Bos, 
Woerdenbag et al. 1997). Recent studies have identified valerenal as one of the major 
constituents of V .officinalis and have established that the valerenal content in valerian essential 
oil increases on aging (Letchamo, Ward et al. 2004). However, in contrast to valerenic acid, no 
studies have been performed with valerenal to investigate its effects on central nervous system. 
In spite of being one of the major constituents of valerian, effects of valerenal remain unknown.  
  
 
Figure 19 EI Mass spectrum of valerenic acid 
 64 
  
Figure 20 EI mass spectrum of acetoxyvalerenic acid 
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Figure 21  EI mass spectrum of valerenal 
 • DISCUSSION 
One of the major constituents of all Valeriana species is the essential oils. Essential oils, 
also known as volatile oils, are generally complex mixtures of volatile organic compounds that 
render the characteristic odor and flavor to the plants. Essential oils can be extracted from 
various plant parts such as leaves, flowers, rhizomes, bark, resin, seeds, fruits or whole plant. In 
case of valerian, the essential oil is present in the roots and rhizomes of the plant.  Previous 
reports on the chemical analysis of the composition of the volatile oil revealed that it was mainly 
composed of terpenoids. 
 
The terpenoids, also called isoprenoids, are one of the largest groups of natural products 
found in nature. Terpenoids are built by the union of two or more five-carbon isoprene units (2-
methylbuta-1, 3-diene) (Figure 22)(Ruzicka 1953; Ruzicka 1994). Most natural terpenoids have 
cyclic structures with one or more functional groups such as hydroxyl or carbonyl groups.  
 
CH2
CH2
CH3
 
Figure 22 Isoprenoid unit 
 
Previous studies have established the presence of both monoterpenoids and 
sesquiterpenoids in valerian. The co-occurrence of the three cyclopentane sesquiterpenoids, 
valerenic acid, acetoxy-valerenic acid, and valerenal, is a characteristic feature of V. officinalis 
 67 
 and distinguishes this species from V. edulis and V. wallichii (Riedel, Hansel et al. 1982).  In 
several studies that have used the bioassay guided assay approach, the dichloromethane extract 
has been shown to possess biological activity (Dietz, Mahady et al. 2005). Consistent with our 
findings, these studies have also shown that this extract is mainly composed of valerenic acid, 
acetoxy valerenic acid and valerenal.  These results support the hypothesis that in addition to 
valerenic acid, acetoxy valerenic acid and valerenal contribute to the inhibition of UGT enzymes.  
However, the potency of each of these compounds is still unknown as they were not available in 
the pure form when these experiments were conducted.  The similarity in the structures of these 
compounds suggests that they could also undergo glucuronidation. Further, valerenal is the most 
abundant of the known sesquiterpenes and the data from this experiment suggests that it could be 
equally or more potent inhibitor of UGT enzymes. Therefore evaluation of the metabolism of 
this compound and identifying the enzymes responsible for its metabolism can provide further 
insight into the interaction potential of valerian preparations. Also, the enzyme catalyzing 
glucuronidation of vaelerenic acid need to be identified in order to determine if valerenic acid is 
capable of interacting with the substrates of some of the other UGT enzymes.   
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 4.0  EFFECT OF VALERIAN ON ACETAMINOPHEN 
PHARMACOKINETICS IN HEALTHY HUMAN VOLUNTEERS 
 69 
 ABSTRACT 
Objective: Valerian is a popular herbal product used as a sedative and anxiolytic agent. 
Most commercially available valerian products are standardized to valerenic acid content. 
Valerenic acid undergoes glucuronidation in vitro indicating that valerian extracts could impair 
conjugation of drugs that are metabolized by this pathway. As acetaminophen is known to be 
extensively glucuronidated, our study was designed to investigate the potential of metabolic 
interaction between valerian and acetaminophen.  
Methods:  The effect of valerian on acetaminophen glucuronidation was evaluated in 
eight healthy volunteers in an open label, two–session fixed sequence design study. The two 
study sessions were separated by one week. Subjects received 500 mg acetaminophen alone and 
in combination with 500mg valerian extract on study sessions 1 and 2 respectively. Subjects self 
administered 500 mg valerian extract at bedtime every night in the week separating the study 
sessions. Acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were 
quantified in plasma and urine samples by HPLC with UV detection.  
Results: Valerian administration increased the acetaminophen absorption rate constant 
(Ka) by 30% from 1.66hr-1 to 2.17 hr-1. Acetaminophen maximum plasma concentration 
(Cmax) was significantly increased (7.9 µg/ml versus 10.6 µg/ml) (p<0.05) and time to reach 
maximum plasma concentration (tmax) was significantly reduced (p<0.05). Valerian did not 
significantly alter acetaminophen, acetaminophen glucuronide or acetaminophen sulfate area 
under the concentration-time curve (AUC) or the terminal elimination half-life (t1/2) of 
acetaminophen. 
Conclusions: These results indicate that valerian is capable of altering absorption rates of 
drugs. This effect is presumably due to an increase in gastrointestinal motility by the effect of 
valerian on gastric smooth muscle. However, significant interactions between valerian and drugs 
undergoing glucuronidation through UGT1A6/9 may not be anticipated. 
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 4.1 INTRODUCTION 
Valerian (Valeriana officinalis) has been used since ancient times as a panacea for 
epileptic seizures, gastrointestinal pain, rheumatism, dysmenorrhoea and low-grade fevers. 
Ancient Greek physicians Dioscorides and Galen are said to have made use of valerian as an 
aromatic and diuretic (Upton 1999).  Currently, Valerian is among the ten most popular herbs 
used primarily for its sedative and tranquilizing effects (Morazzoni and Bombardelli 1995; 
Vickers, Zollman et al. 2001).  Results of clinical trials support the assumption that valerian may 
be effective in treating insomnia (Stevinson and Ernst 2000).  
In spite of its wide-spread use, specific scientific data regarding pharmacokinetics of its 
constituents and drug interaction potential is lacking. Although data from in vitro studies 
indicated that valerian could inhibit drug metabolizing enzymes CYP3A4 and CYP2C19 
(Lefebvre, Foster et al. 2004; Strandell, Neil et al. 2004), results of an in vivo study in humans 
suggests that valerian does not alter CYP3A4 or CYP2D6 activities (Donovan, DeVane et al. 
2004).  The constituents of Valerian include valerenic acids, valepotriates, flavonoids and 
alkaloids(Dewick 2002).  Most commercial products are standardized to valerenic acid content 
as it is believed to be the active constituent of valerian (Hendriks, Bos et al. 1981).  As 
compounds containing carboxylic acid groups often undergo phase II metabolism by 
glucuronidation pathway, valerenic acid could be conjugated with glucuronic acid thereby 
interacting with substrates undergoing glucuronidation.  Acetaminophen is known to undergo 
extensive metabolism by glucuronidation and has often been used both in vitro and in vivo as a 
probe substrate to determine the effects of drugs and endobiotics on glucuronidation.  The 
objective of our investigation was to determine the effect of Valerian administration on the 
pharmacokinetics of acetaminophen and its glucuronide in healthy volunteers. 
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4.2 METHODS 
4.2.1 Drugs and reagents 
Valerian root extract capsules (Pharmassure, Phoenix AZ) and acetaminophen (Tylenol 
extra-strength, McNeil Consumer & Specilaity Pharmaceuticals, Fort Washington, PA) were 
purchased locally. Acetaminophen, acetaminophen glucuronide (APAPG) and acetaminophen 
sulfate (APAPS) for HPLC assay were purchased from Sigma (St Louis, MO).  All chemicals 
were of analytical grade.  
4.2.2 Subjects 
Eight healthy volunteers (four male, four female) age: 22-40 years; 49-105kg were 
enrolled in the study. The study was approved by the University of Pittsburgh biomedical 
institutional review board and was conducted in the General Clinical Research Center of the 
University of Pittsburgh Medical center. Written informed consent was obtained from all 
subjects. All subjects underwent a screening history and physical examination to verify health 
status. Subjects were excluded if they were regular cigarette smokers, used any medications 
(except oral contraceptives) or herbal products, were pregnant or breastfeeding. 
4.2.3 Study Design 
This was an open-label, fixed-sequence interaction study. Intake of alcohol and caffeine 
was not permitted 24 hrs prior and grapefruit juice 48 hrs prior to the study sessions. During 
study session 1, subjects received 500 mg acetaminophen alone and during study session 2, 
subjects received 500 mg acetaminophen and 500 mg valerian extract together. Subjects were 
provided standardized meals during the study sessions. Blood was obtained for determination of 
concentrations of acetaminophen, acetaminophen glucuronide and acetaminophen sulfate at 0 
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 hours (30 minutes prior to dose) and at 0.25, 0.5, 1, 2, 3, 4, 6 and 8 hours after dose. Urine was 
collected in intervals of 0-8 hrs and 8-24 hrs. In the week separating the two study sessions, 
subjects were instructed to self-administer two valerian capsules daily within two hours of 
bedtime. Subjects were also instructed to keep a diary and note the times at which the dose was 
taken on each night in order to monitor adherence.   
4.2.4 Sample collection and processing 
Blood samples (3ml) were placed on ice immediately after collection and centrifuged 
within 15 minutes. The resultant plasma was stored at -80oC until analyzed. Urine samples were 
stored refrigerated until the end of the collection interval; after collection, the total volume was 
measured and aliquots were frozen at -80oC until analyzed. 
4.2.5 Assays 
Acetaminophen, acetaminophen glucuronide and acetaminophen sulfate were measured 
in plasma and urine using a modified HPLC method (Chapter 2) with UV detection described 
previously (Alkharfy and Frye 2001). Briefly, 250µl plasma was treated with 25µl 6% perchloric 
acid and centrifuged at 14,000g for 5 minutes.  A 50µl aliquot of the supernatant was injected 
into the  HPLC system. The HPLC system consisted of Waters model 717 autosampler, model 
501 HPLC pump and model 486 ultraviolet detector set at 254 nm (Waters corp., Milford, MA, 
USA). Detection and quantification were performed using Empower 2 software (Waters, Corp., 
Milford, MA, USA). Separation was achieved with a Waters Symmetry® C18, 5µ, 150 mm × 3.9 
column (Waters corp., Milford, MA, USA) and with isocratic flow of mobile phase composed of 
10% methanol and 1% acetic acid in 100 µM phosphate buffer. Acetaminophen and its 
metabolites were detected at 254 nm. Acetaminophen concentration in plasma was quantitated in 
duplicate from a standard curve that was linear (r 2 = 0.995) over the range of 0. 5 to 20 µg/mL, 
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 with a intraday and interday and coefficients of variation <10%. Acetaminophen in urine was 
also assayed by the method described above. Acetaminophen, acetaminophen sulfate, and 
acetaminophen glucuronide were quantitated from unhydrolyzed urine. 50 µl of the supernatant 
was injected onto the HPLC column, and the glucuronide, sulfate, and acetaminophen were 
eluted with retention times of 3.5, 5.8 and 6.7, respectively. 
4.2.6 Pharmacokinetic analysis 
Acetaminophen concentration-time data for each individual data set was analyzed using 
WinNonlin® version 4.01 (Pharsight Corporation, Mountain View, CA, USA) and a one-
compartment open model with first-order absorption and first-order elimination. This model was 
chosen based upon the Akaike Information Criterion (AIC) and a visual analysis of the curve fits 
and residual plots. The primary parameters calculated included the apparent volume of 
distribution (Vd/F), the absorption rate constant (Ka) and the elimination rate constant (Kel). The 
secondary parameters calculated were the area under the curve from time zero to infinity(AUC0-
∞), and the half-lives of absorption and elimination (t1/2a and t1/2el) respectively. Individual area 
under the plasma concentration time curves from time 0-8 hrs (AUC0-8) after dose was calculated 
by the linear-log trapezoidal method. The maximum plasma concentration (Cmax) and time to 
reach Cmax (tmax) were determined directly from the observed plasma concentration-time profiles 
over the 8 hour sampling period. Apparent oral clearance (CL) was calculated as dose/ AUC 0-∞. 
Formation clearance of the metabolites was calculated as  
fm * CLAPAP   where  fm = Amount recovered in urine/dose 
4.2.7 Statistical Analysis 
Results are expressed as mean values ± SD in the text and tables and, for clarity, as mean 
values ± SEM in the figures. The differences in the pharmacokinetic variables were compared by 
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 use of a paired t test or, in the case of tmax, by the Wilcoxon signed rank test. The differences in 
the pharmacokinetic parameters were assessed by 90% confidence intervals (CIs) for the 
geometric means ratio of valerian treatment over control. A lack of interaction was concluded if 
these 90% CI values fell within the range of 0.8 to 1.25.  Statistical analyses were conducted 
with GraphPad InStat software (GraphPad Software for Science Inc, San Diego, Calif). A P 
value less than 0.05 was considered to be statistically significant.  
4.3 RESULTS 
The mean plasma concentration time profiles of acetaminophen, acetaminophen 
glucuronide and acetaminophen sulfate are shown in Figures 23 and 24. The effects of valerian 
extracts on peak plasma acetaminophen concentration, time to reach peak plasma concentration, 
clearance, and elimination t1/2 for individual subjects are given in Table 8. Valerian treatment 
increased maximum plasma acetaminophen concentration by 47% (P < 0.05) as shown in Figure 
25.  This was accompanied by a 10% decrease in time to peak concentration (P < 0.05).  There 
was no change in elimination t1/2 or clearance caused by valerian. 
Acetaminophen and its metabolites were measured in the urine and the formation 
clearance of the respective metabolites is shown in Table 9. The assumption was that recovery of 
the acetaminophen dose was complete and unaffected by valerian treatment. Glucuronidation and 
sulfation were the major routes of acetaminophen elimination. 
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Figure 23  Mean (±SE) plasma acetaminophen concentration time profile with ( ) and   
( ) without valerian  
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Figure 24 Concentration time profile with and without valerian for acetaminophen 
glucuronide and acetaminophen sulfate 
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 Table 8 Plasma acetaminophen pharmacokinetic parameter estimates 
 
Parameter Control Valerian Geometric  
Mean ratio 
90% CI p value 
Ka (hr-1) 1.66 + 0.807 2.17+ 0.810 1.73  1.62- 1.85 0.0202 
Cmax (µg/l) 7.9 + 2.9 10.6 + 2.4 1.25   1.11-1.41 0.0235 
Tmax (hr) 0.7 (0.5 - 0.9)* 0.6 (0.6 - 0.7) * - - 0.0208 
AUC (hr*µg/l) 23.5+ 5.6 25.05 + 4.4 1.14   1.29- 1.00 0.2493 
CL (ml/min) 372.8 +  19.9 341.0 +  54.9 0.88  0.77-0.99 0.2672 
* tmax given as median and range 
 
 
 
 
Table 9 Pharmacokinetic parameters of metabolites 
Parameter Control Valerian 
AUAPAPG 58.9 ± 4.9 55.3 ±  13.1 
AUAPAPS 30.9 ± 3.4 32.3 ± 6.2 
Clf_Gluc 203.33 ±  51.5 193.5 ±  83 
Cl f _Sulf 67.5 ±  24.7 55.17 ± 16.5 
AU Amount recovered in the urine as  percent of dose  
Clf_Gluc   Formation clearance of APAPG , Cl f _Sulf  Formation clearance of APAPS 
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Figure 25  Effect of valerian administration on acetaminophen maximum plasma 
concentration (Cmax) and time to reach Cmax  (t max)   
Box and whisker plots for comparison of (A) Cmax  and (B) tmax without and with 
valerian administration The box represents lower to upper quartiles (25th to 75th 
percentiles). The line in the box represents the median and the whiskers indicate the 
extent of the data. 
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 4.4 DISCUSSION 
While a significant amount of data has emerged on the modulatory effects of botanicals 
such as St. John’s wort, data on valerian products remain scarce in the medical literature. The 
few studies that have investigated Valerian are limited to cytochrome P450 enzymes. This is the 
first study investigating the interaction potential of Valerian by taking into consideration the 
chemical structure of valerenic acid and its capability to undergo glucuronidation.  Our findings 
suggest that the generally recommended dosage of valerian is unlikely to significantly alter the 
disposition of coadministered medications primarily metabolized by UGT1A6/9, which are the 
enzymes responsible for acetaminophen glucuronidation. This conclusion is based on the finding 
that there were no significant differences in acetaminophen AUC or terminal elimination half-
life. 
An interesting finding of this study was the significant change in the maximum 
concentration in plasma and time to reach this maximum concentration. A similar effect was 
reported by the study investigating the effect of valerian administration on the CYP3A substrate 
alprazolam in humans. However, the cause of the increased absorption rate of alprazolam after 
valerian administration remains unknown. Among other effects, ancient medical texts suggest 
that valerian has a relaxing effect on the gut wall. In addition, valerian has been used in folk 
medicine to treat gastrointestinal pain and flatulence. An earlier study alluded to antispasmodic 
activity of valerian on gastric smooth muscle (Wagner and Jurcic 1979). This effect was 
confirmed in a later study using isolated pig-ileum (Hazelhoff, Malingre et al. 1982). In this 
study, valerenic acid, valtrate and valeranone were shown to exert papaverine–like spasmolytic 
effects on the smooth muscle. The use of acetaminophen as a substrate in our study had an added 
advantage that it has often been used  to evaluate gastric emptying motor ability (Clements, 
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 Heading et al. 1978; Harasawa, Tani et al. 1979; Mizuta, Kawazoe et al. 1990; Cavallo-Perin, 
Aimo et al. 1991; Feng, Li et al. 1996; Nakamura, Takebe et al. 1996; Hasebe and Harasawa 
1997; Sanaka, Kuyama et al. 2002; Gandia, Bareille et al. 2003). The increased absorption rate of 
acetaminophen strongly suggests that valerian increases gastric emptying rate. This effect of 
valerian could also explain the increase in absorption rate observed with the alprazolam in the 
previous study. Although pharmacokinetic interactions with valerian can be ruled out based on 
this study, the change in absorption rate could have implications for effects of drugs acting 
centrally.  
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 5.0  EVALUATION OF EFFECT OF VALERIAN EXTRACTS ON 
ACETAMINOPHEN GLUCURONIDATION IN HUMAN HEPATOCYTES 
 82 
  83 
  
5.1 INTRODUCTION 
Herbal products are used for a variety of reasons. Survey reports suggest that most often 
herbal products are used in treatment of chronic conditions such as insomnia, depression and 
post menopausal symptoms. A majority of herbal users use them on a daily basis and a 
significant number use them for a prolonged amount of time, some as long as three years. As 
with drugs, these patterns of use can affect the mechanism of drug interactions. While a single 
dose of the product may inhibit the enzyme, chronic use can result in induction of enzymes.  A 
classic example of this phenomenon is HIV protease inhibitor, ritonavir which is both an 
inhibitor and inducer of CYP3A4 (Kageyama, Namiki et al. 2005). A similar phenomenon is 
reported for troleandomycin (Luo, Cunningham et al. 2002).  Among herbs, hyperforin, a 
constituent of St. Johns wort is reported to have a similar effect on CYP3A4. Chronic exposure 
of hyperforin resulted in an increase in the CYP3A4 activity while acute exposure to hyperforin 
resulted in the inhibition of the enzyme.  
Based on our preliminary studies with human liver microsomes, we hypothesized that the 
mechanism of interaction would be inhibition. However, the results of the clinical study did not 
support the hypothesis that the pharmacokinetics of acetaminophen would be altered by valerian 
administration. This could be because of the following reasons  
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 a)  The inhibition observed in the microsomal system was dose dependent and the concentration 
of the extracts was high enough to cause the inhibition, whereas in the clinical study these 
high concentrations were not achieved in vivo.  
b) Administration of valerian for one week induced the UGT enzymes, which offset any 
potential inhibitory effects. Therefore, the enzyme levels did not change and the 
pharmacokinetic parameters of acetaminophen remained unaltered.  
We hypothesized that compounds in valerian including valerenic acid will have a dual effect on 
UGT enzymes. Our hypothesis was further supported by the fact that valerenic acid (100 µM) 
was shown to activate PXR in reporter gene assays (Unpublished data from Dr. Wen Xie’s lab 
through personal correspondence, Center for Pharmacogenetics, University of Pittsburgh, and 
School of Pharmacy).  In order to investigate if this phenomenon occurs, based on the 
advantages and availability we selected the hepatocyte model. This model system is capable of 
measuring enzyme induction in addition to enzyme inhibition.  
5.1.1 Models for metabolism studies 
Various in vitro models have been used to study hepatic metabolism of drug molecules 
and other xenobiotics. These models have also been used to predict metabolic drug interactions 
(Ito and Houston 2004).  The models are classified mainly into two types, cell-free systems/ 
homogenates and whole cell preparations. The cell–free systems include liver microsomes, S9 
fractions and purified or heterologously expressed enzyme systems. Human liver microsomes are 
vesicles of endoplasmic reticulum obtained by differential centrifugation of cell homogenate. 
Owing to their ease of preparation, commercial availability, and long-term stability, these 
systems are most commonly used to generate preliminary information on the effect of drugs or 
xenobiotics on specific CYP or UGT enzymes and to screen for potential drug-drug interactions. 
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 Moreover, their adaptability to high throughput techniques has led to their widespread use in 
metabolism studies. The cell free systems require supplementation of exogenous cofactors, such 
as a source of NADPH for CYP enzymes or conjugating moieties for phase II enzymes. These 
systems are not appropriate to study sequential metabolic reactions (i.e., the coupling of phase I 
and II reactions) due to the disruption of cellular integrity.  The limitation of cell free systems is 
their suitability only for enzyme inhibition studies. 
The whole cell systems used in drug metabolism studies are liver slices and intact 
hepatocytes. In these systems, gene expression, metabolic pathways, cofactors/enzymes and 
plasma membrane are largely preserved.  Because of these characteristics, they serve as excellent 
models to test effects of drugs on enzyme induction and transport.   Liver slices and hepatocytes 
are also suitable models to study sequential and/or parallel oxidative and conjugative 
biotransformation (Beamand, Price et al. 1993; Lake, Beamand et al. 1993). Although liver slices 
are relatively simple to use and their viability is longer than microsomes, they are not viable for 
enough time to study induction of enzymes (Berthou, Ratanasavanh et al. 1989). In this regard, 
hepatocyte cultures are viable for longer periods of time compared to liver slices.  Hepatocyte 
cultures used in metabolism studies require the first 24 hours for adaptation of cells to culture 
conditions, thereafter remaining quite stable for a few days. In many respects they are the closest 
systems to in vivo models and have all the advantages of whole cell preparations.  
5.1.2 Regulation of UGTs 
One of the principal mechanisms of increased enzyme activity is by up regulation of gene 
expression. The expression of genes for drug metabolizing enzymes is controlled by several 
factors. Most of these factors regulate the gene expression at the mRNA transcription stage and 
to a smaller extent, mRNA splicing and translation stages.  The genes contain specific regulatory 
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 sequences called promoters that determine both the basal transcription of the gene and its 
response to specific stimuli. Regulatory proteins known as transcription factors bind to the gene 
promoter and activate or inhibit transcription. Transcription factors such as Hepatocyte Nuclear 
Factor 1 (HNF1), CAAT-Enhancer Binding Protein, Octamer transcription Factor 1 and Pre-B-
cell leukemia transcription factor-2 (Pbx2), appear to control the constitutive levels of UGTs in 
tissues and organs  (Mackenzie, Gregory et al. 2003). Activation of transcription factors occurs 
as a direct result of ligand binding or as an indirect result of phosphorylation or 
dephosphorylation of one or more transcription factors (Treisman 1996). Members of nuclear 
receptor family such as aryl hydrocarbon receptor (AhR), constitutive androstane receptor (CAR) 
and pregnane X receptor (PXR) represent the ligand-activated transcription factors 
(Mangelsdorf, Thummel et al. 1995). The nuclear receptors involved in regulation of phase I and 
phase II enzymes and their activators are shown in Table 10. Generally, the transcriptional 
regulation via CAR and PXR involves the formation of heterodimers between these receptors 
and retinoid X receptor (RXR) followed by binding of the heterodimer to response elements in 
the regulatory region of target genes, and transactivation of gene expression. This paradigm of 
the mechanism of induction by ligand-activated gene expression is represented in Figure 26. The 
example shows the activation of the aryl hydrocarbon receptor (AhR) on binding with an agonist, 
followed by dimerization of AhR with the Ah receptor nuclear translocator (Arnt) and  
translocation into the nucleus where the AhR / Arnt heterodimer binds to the dioxin-responsive 
enhancer (DRE) resulting in transcription of the gene (Ma 2001). Early studies showed that UGT 
enzymes were inducible by phenobarbital, and phenytoin (Brierley, Senafi et al. 1996).  In the 
past several years, the nuclear receptor PXR has been implicated as a key mediator in regulation 
of cytochromes P450 as well as UGTs in many species (Bertilsson, Heidrich et al. 1998; 
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 Blumberg and Evans 1998; Kliewer, Moore et al. 1998; Xie, Barwick et al. 2000). There is 
evidence from transgenic mouse studies that UGT1A1 and UGT1A6 are regulated by PXR and 
CAR (Xie, Yeuh et al. 2003). In the same study, treatment with prototypical inducers, rifampin 
and clotrimazole caused significant activation of the UGT reporter genes by the human PXR, 
further establishing the role of these nuclear receptors in the regulation of UGT enzymes.  Recent 
studies have demonstrated that in addition to PXR and CAR, AhR also plays a regulatory role in 
the induction of UGT1A1 by characterization of a phenobarbital (PB) response enhancer module 
in the gene promoter region (Sugatani, Kojima et al. 2001). 
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 Table 10  Nuclear receptors and their activators 
 Nuclear Receptor Activators 
 AhR Arochlor 1254 
Dioxin 
3-methylcholanthrene 
PXR Dexamethasone, 
Rifampin, 
Phenobarbital, 
Hyperforin,  Bile acid 
CAR Androgens, Rifampin, 
Phenobarbital 
PPAR γ Fatty acids, 
Prostaglandins 
Leukotrienes  
FXR Bile acids 
 
 
 
ORPHAN 
RECEPTORS 
 
LXR Oxysterols 
VDR Lithocholic acid 
GR Cortisol 
RAR All-trans-retinoic acid  
MR  Aldosterone 
ER 17 β estradiol 
PR Progesterone 
 
 
 
ENDOCRINE 
RECEPTORS 
AR Oxysterols 
Adpated from Carlberg C. Principles of gene regulation by bioactive lipids through members of 
the nuclear receptor superfamily.  Mechanisms of Signal Transduction and Inducible Gene 
Expression, 2004: 77-95 (Key : AhR Aryl hydrocarbon receptor,  PXR pregnane X receptor, 
CAR constitutive androstane receptor, PPAR γ Peroxisome proliferator-activated receptor 
Gamma,   FXR Farnesoid X-receptor,  LXR Liver X receptor,  VDR Vitamin D Receptor ,  GR 
Glucocorticoid Receptor,  RAR retinoic acid receptor , MR Mineralcorticoid Receptor,  ER 
Estrogen receptor,  PR Progesterone receptor,  AR Androgen Receptor ) 
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Figure 26 Mechanism of action of nuclear receptors.  
In the absence of a ligand, the  receptor is  usually is in the cytoplasm due to 
their association with a large multiprotein complex of chaperones, such as  
Hsp90. Ligand binding induces dissociation of the complex and nuclear 
translocation. Once in the nucleus, the receptors regulate transcription by 
binding, generally as dimers, to drug response elements (DREs) normally 
located in regulatory regions of target genes.  
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 5.1.3 Real-time PCR 
Quantification of gene expression has been traditionally performed by measuring mRNA 
levels by northern blotting, in situ hybridization and RNAse protection assays, and reverse 
transcription polymerase chain reaction (RT-PCR) (Wang, Doyle et al. 1989; Hod 1992; 
Saccomanno, Bordonaro et al. 1992; Parker and Barnes 1999) (Weis, Tan et al. 1992). These 
methods are often laborious and time-consuming. Moreover, they require post-PCR processing 
such as running gels or transfer to membranes and results are often semi-quantitative (Sharp, 
Berk et al. 1980; Thomas 1980). The real-time PCR technique is simple, fast, precise, accurate 
and reproducible for quantitative determination of the mRNA (Higuchi, Fockler et al. 1993; 
Gibson, Heid et al. 1996; Heid, Stevens et al. 1996). The real-time PCR technique is based on 
fluorescence detection during the entire PCR amplification process. A dually labeled fluorescent 
probe hybridizes to the template in each cycle and an amplification plot of fluorescence signal 
versus cycle number is generated.  The initial cycles of PCR, when there is little or no change in 
fluorescence signal is defined as the baseline for the amplification plot. An increase in 
fluorescence above the baseline indicates the detection of accumulated PCR product. A fixed 
fluorescence threshold is set abovethe baseline and the parameter threshold cycle (CT) is defined 
as the fractional cycle number at which the fluorescence passes the fixed threshold. Instead of 
obtaining concentrations at the end of the reaction as is the case with most conventional methods, 
quantification of DNA in real time-PCR is based on measurements obtained during the early 
exponential phase. During this phase, the amount of the amplified product is proportional to the 
concentration of the template versus CTs for a set of standards. Concentrations of DNA of the 
unknown samples are determined from the standard curve using the CTs of the samples.    
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 5.2 EXPERIMENTAL 
5.2.1 Chemicals 
Williams’ E culture medium and medium supplements, dexamethasone and insulin, were 
obtained from Cambrex BioScience Walkersville, Inc. (Walkersville, MD). Penicillin 
G/streptomycin was obtained from Invitrogen (Carlsbad, CA). Phenobarbital (PB), 
dexamethasone (DEX), acetaminophen and acetaminophen glucuronide were obtained from 
Sigma (St. Louis, MO). Reagents for reverse transcription were purchased from Promega 
(Madison, WI). Forward and reverse primers for β-actin were synthesized by Applied 
Biosystems (Foster City, CA). Universal Taqman Master Mix® and TaqMan® Gene Expression 
Assay system (assay ID : Hs01592477_m1)for UGT1A6 and (assay ID: Hs01592475_m1 )for 
UGT1A9 were purchased from Applied Biosystems. All solvents and other chemicals used were 
of HPLC grade or the highest purity available. Falcon culture dishes (100 mm and six well plates 
were purchased from Becton Labware (Franklin Lakes, NJ) 
5.2.2 Isolation and culturing of primary human hepatocytes 
Human hepatocytes are isolated by the three step collagenase perfusion technique. 
(Strom, Pisarov et al. 1996). Briefly, the liver was perfused with a buffered isotonic salt solution 
to eliminate blood cells and other components, then with collagen/dispase medium to digest the 
liver into individual cells or small clusters, and finally with a culture medium containing 
collagen type I to reorganize the multicellular architecture. The perfusion solutions and liver 
tissue were maintained at 37°C during perfusion. The digested tissue was collected and filtered. 
The hepatocytes were then purified by washing and the cell number estimated. Viability of the 
isolated cells was determined prior to plating by the trypan blue exclusion test. Acceptable 
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 viability was 70% or higher.  The hepatocytes (1.5 × 106) were plated on six-well culture plates 
previously coated with rat-tail collagen. The hepatocytes were plated in Williams E medium 
supplemented with 0.1 µM dexamethasone, 0.1 µM insulin, 0.05% gentamicin, and 10% bovine 
calf serum. Cells were allowed to attach for 4h. Culture medium was replaced with medium 
containing all the above mentioned supplements except bovine calf serum. The hepatocyte 
cultures were maintained at 37°C in a humid atmosphere containing 5% CO2 in air until harvest. 
The cells were washed and medium replaced every 24 h. For the acute study, valerenic acid 
(50µM), ethanol (120µg), dichloromethane (40µg) and ethyl acetate (15µg) extracts in dimethyl 
sulfoxide (DMSO; 0.1% final concentration in medium) was added to the hepatocytes at 95 h of 
culture. For the chronic study, valerenic acid and the extracts were added to the culture at 48 and 
72 h after plating.  Donor information for the hepatocytes used in this experiment is described in 
Table 11   
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 Table 11  Donor information for human hepatocyte preparations used  
Donor 
HH #  Age  Sex
a 
 Race
b 
 
Cause of 
death c
 
 Drug History  Viability
1118 74y F C HT/MVA 
Hydrochlorothiazide, paxil, lasix, 
atenolol, imipramine, enalaprilat, 
pepcid, aspirin, calcium 
76 
1119  29y  F  C  -  None reported  75 
1121 65y F C ICH None reported 78 
1122  46y  F  C  HT  
alprazolam, capoxone, verapamil, 
levothyroxine, modafanil, 
propranolol, triamterine,  
73  
1124 70  M  H  ICH  Amitriptyline, nifedipine  70 
1215 36 M AI CA None reported 82 
1217 60 M C CA None reported 81 
1218  50 F C Anoxia None reported 85 
a
M, male; F, female; 
b
C, Caucasian; H, Hispanic, AI American Indian; 
c 
CA, cardiac 
arrest; HT, head trauma; ICH, intra cranial hemorrhage. 
  
5.2.3 Evaluation of cytotoxicity 
Hepatocytes were exposed to 50µM troglitazone (positive control), 50 and 100µM 
valerenic acid and 10µg/ml of valerian extracts for 48 h. Media was aspirated and 2ml of 0. 5 
mg/ml 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was added to 
Williams’ E medium at 96 h of culture and incubated for 30 min. At 30 min, the medium was 
aspirated and cells washed with Williams’ E culture medium. Isopropanol (same volume as the 
medium) was then added to each well and shaken gently for 2 minutes. The isopropanol solution 
(200µl) was transferred to a 96-well plate, and the absorbance was measured at 490 nm. 
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 5.2.4 Evaluation of activity 
Two sets of experiments were performed, each set composed of hepatocyte cultures from 
three different human donors. One set of experiments were performed to evaluate the effect of 
acute exposure to valerenic acid and valerian extracts on UGT activity. For these experiments, 
the hepatocytes were cultured for 3 days with daily medium change. On day 4 (after 95 hours in 
culture), cells were exposed to HMM (negative control) or media containing PB (2mM; positive 
control), valerenic acid (50µM), ethanol (120µg), dichloromethane(40µg) or ethyl acetate(15µg) 
extracts in DMSO (0.1% final concentration) for 1 hour. At 96 hours, the hepatocytes were 
washed with fresh medium devoid of any supplements and incubated at 37°C with fresh medium 
for an hour.  The hepatocytes were then exposed to a medium containing acetaminophen (5 mM) 
in water for 1 hr. This concentration of acetaminophen was based on previous studies where 
maximum formation of metabolite was observed at 5mM.  The formation of APAPG was shown 
to be linear up to 120 min and for these experiments APAP was incubated for 60min. At the end 
of this time period the reaction was terminated by adding 125µl of 70% perchloric acid and the 
entire cellular components and medium were harvested. The sample was centrifuged at 2000 g 
for 5 min, and the supernatant was transferred into new vial and stored at -20°C until analysis. 
Phosphate buffer (250µl) was added to the residue containing the cellular components and stored 
at -80°C.  Another set of experiments were performed to evaluate the effect of chronic exposure 
to valerenic acid and valerian extracts. For these experiments, cells were exposed to HMM 
(negative control) or media containing PB (2mM; positive control) in addition to valerenic acid 
and valerian extracts  as described for acute exposure, for 3 days after plating, with media change 
daily.  On day 4, cells were washed and incubated for 1 hour with media, followed by incubation 
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 with APAP for 1 hour to evaluate UGT activity. Media and cells were harvested as described 
before. 
5.2.5 Estimation of metabolite formation 
The medium stored at -20°C was thawed and 75µl of the sample was injected onto 
Symmetry C18 column with a mobile phase of MeOH: Acetic acid (10:1) at a flow rate of 1 
ml/min. APAPG was detected using UV absorbance at 254 nm. The concentration of the 
metabolite was quantitated by comparing the peak areas in samples to a standard curve 
containing known amount of the metabolite.  Metabolite formation rate was calculated from the 
amount of APAPG in mg/ min.  
5.2.6 Total protein estimation 
The cells stored at -80°C were thawed and protein concentration was estimated by 
Lowry’s method.  Briefly the proteins were dissolved in 0.1M sodium hydroxide and mixed with 
1ml 2 % sodium tartarate and 1ml 1% copper sulfate. Folin-Ciocalteu reagent was added to this 
mixture and the tubes were mixed gently. Color was allowed to develop for 60 min. At the end of 
60 min. the solutions were transferred to 96 well plates and absorbance measured at 490 nm. The 
concentration of the protein was calculated from a standard curve prepared with bovine serum 
albumin (BSA) as a protein standard.  
5.2.7 Evaluation of mRNA expression 
Hepatocyte treatments were the same as for chronic exposure. After 96 hours in culture, 
total RNA was extracted from the cells using 1 mL Trizol reagent (Invitrogen, Carlsbad, CA) 
according to manufacturer’s instructions. The integrity of the isolated RNA was assessed by 
agarose gel electrophoresis and RNA concentration was measured by spectrophotometry. 
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 Quantification of mRNA levels was performed using a quantitative RT-PCR technique. Reverse 
transcription of mRNA to cDNA was performed by a three step procedure. As total RNA 
isolated using routine methodologies are frequently contaminated with DNA, RNA was first 
treated with RNase-free DNase (Promega, Madison, WI) to remove genomic DNA 
contamination. Next, the synthesis of cDNA was primed by combining 2 µg of RNA with 0.5 µg 
of random hexamers (Promega) and incubating the samples at 70°C for 5 minutes. Samples were 
cooled to 4°C and the final step was the addition of reverse transcription mixture containing the 
reverse transcriptase, dNTPs and RNasin (Promega) to the previous mixture and incubation at 
37°C for 60 minutes. The resulting cDNA was diluted 10-fold and stored at -20°C. Real time 
PCR was performed for quantification of UGT1A6 and UGT1A9 mRNA by Taqman® PCR 
reactions using the Perkin Elmer 7700 Sequence Detection System®. For an internal control, β-
actin mRNA was measured in each sample using predeveloped TaqMan assay reagents for 
human β-actin (Applied Biosystems). Each 20 µl total volume PCR reaction contained 12.5 µl 
Universal Taqman Master Mix®, 1.25 µl of TaqMan® Gene Expression Assay system 
(Hs01592477_m1) for UGT1A6 and (Hs01592475_m1 ) for UGT1A9 and 5 µl of cDNA 
generated or standard. The following conditions were used for the Taqman® PCR reactions: 2 
minute hold at 50°C, 10 minute hold at 95°C, 50 cycles of 95°C for 15 seconds and 60°C for 1 
minute. The 50 cycles were followed by a 4°C hold. . A standard curve was generated from a 
cDNA dilution series ranging from 0.01 to 1ng.  Values for mRNA levels of UGT 1A6 and 
UGT1A9 in each experimental sample were extrapolated from the standard curve, normalized to 
β-actin mRNA and expressed as fold change compared to DMSO control.  
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 5.2.8 Data Analysis  
Statistical analysis was performed using the PRISM software version 4.0 (GraphPad 
Software, Inc., San Diego, CA, USA). Results are expressed as means ± standard deviation from 
at least three independent experiments. Statistical significance of the difference between the 
control and the test groups were analyzed using a one-way analysis of variance with a post hoc 
Dunnett’s procedure. A p value of ≤ 0.05 was considered statistically significant.  
5.3 RESULTS 
5.3.1 Cytotoxicity of valerenic acid and extracts of valerian 
Hepatocytes (HH118, HH1122, HH1124) were exposed to valerenic acid (50µM), 
ethanol (120µg), dichloromethane (40µg) and ethyl acetate (15µg) extracts of valerian dissolved 
in DMSO. Cytotoxicity was compared to untreated hepatocytes and troglitazone 50µM as 
positive control. The direct reduction of MTT tetrazolium salt as a measure of decreased 
mitochondrial activity, by the test agents was determined by spectrophotometry. Valerenic acid 
as well as the extracts at the concentrations used showed no reduction in mitochondrial activity 
as shown in the Figure 27 indicating that the compounds at the concentrations tested were devoid 
of cellular toxicity.  
5.3.2 Effect of Acute exposure of valerenic acid and valerian extracts on UGT activity 
The formation of acetaminophen glucuronide was determined after acute exposure to 
valerenic acid and valerian extracts in three cultures (HH1118, HH1121 and HH1122).  For each 
treatment, the activity relative to the DMSO control was calculated. The acetaminophen 
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 formation rate in control hepatocytes ranged from 112 to 182 pmol/min/mg protein. In contrast 
to results from microsomal studies, acute exposure to the alcoholic extract did not cause 
biologically significant inhibition of UGT activity. However, significant inhibition of UGT 
activity was observed with both concentrations of valerenic acid as well as the dichloromethane 
and ethyl acetate extracts tested. With both concentrations of valerenic acid 50µM and 100µM, 
APAP-G formation rates were inhibited to 64% ± 4.8 % and 46 % ± 6.7% of DMSO control, 
respectively. The Valerian alcoholic, dichloromethane and ethyl acetate extracts inhibited 
APAPG formation by 71 ± 16 %, 46± 4.2% and 38±5.4% respectively (Figure 28A). 
5.3.3 Effect of Chronic treatment of valerenic acid and valerian extracts on UGT activity 
The induction potential of valerenic acid and valerian extracts was tested by the chronic 
exposure experiments. Induction potential was compared to potent human UGT inducer, PB. PB 
was consistently a more potent inducer than valerenic acid and valerian extracts. In the three 
cultures tested (HH1119, HH1121 and HH1122), PB induced UGT activity to 2.8, 2.6 and 1.8 
fold over DMSO control. All three valerian extracts also significantly induced UGT activity with 
the increased activity levels with the ethyl acetate extract approaching that of PB in all three 
cultures. The induction levels were 1.6, 2.0 and 2.2 fold that of DMSO control for the alcohol 
extract, dichloromethane extract and ethyl acetate extract respectively (Figure 28B).  
5.3.4 Effect of valerenic acid and valerian extracts on UGT mRNA expression 
Estimation of mRNA levels of UGT1A6 and UGT1A9 in three human hepatocytes 
cultures (HH1215, HH1217 and HH1218) was carried out by quantitative RT-PCR. Treatment 
with PB increased the mRNA levels of UGT1A6 by 4.3, 7.9and 8.9 folds over the DMSO control 
and UGT1A9 levels by 55, 47 and 85 fold over control in the three cultures, respectively.  
Valerenic acid (50 µM), alcoholic extract, the dichloromethane and the ethyl acetate extracts 
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 increased UGT1A6 mRNA levels by 4.0 ± 0.8 , 2.4 ± 1.1, 5.1 ± 0.8 and 6.1 ± 1.3 (mean ± sd) 
fold over control (Figure 29A). Valerenic acid (50 µM) and the alcoholic extract did not cause a 
statistically significant increase in UGT1A9 mRNA. The valerian extracts increased UGT1A9 
mRNA levels by 11 ± 7.3, 21 ± 12.7 and 34 ± 17.7 fold over control (Figure 29B).  
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Figure 27 Effect of valerenic acid and valerian extracts on MTT reduction. 
Hepatocytes were treated valerenic acid, and valerian extracts and compared 
with troglitazone treatment. MTT reduction was then measured. The figure 
shows the mean of triplicate treatments in three donors (HH118, HH1122, 
HH1124) and are expressed as a percentage of the value in DMSO treated 
cells, with the S.D. indicated by the vertical bars. ** significantly different 
from DMSO treated cells, p ≤ 0.01. 
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Figure 28  Effect of acute (A) and chronic (B) treatment of valerenic acid and valerian 
extracts on APAP glucuronidation 
Hepatocytes were treated with valerenic acid and valerian extracts A. acute  (1 hr 
exposure,) and B. chronic (72 hrs exposure, HH1118, HH1121 and HH1122). The figure 
shows the mean of triplicate treatments, with the S.D. indicated by the vertical bars. * 
indicates p≤0.05 ** indicates p≤0.01 compared to DMSO control. 
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Figure 29 UGT1A6 (A) and UGT1A9 (B) mRNA expression after chronic treatment with 
valerenic acid and valerian extracts. 
Hepatocytes were treated with valerenic acid and valerian extracts for 72 hrs  
A) UGT1A6 mRNA expression, B) UGT1A9 mRNA expression. The figure shows 
the mean of triplicate treatments, with the S.D. indicated by the vertical bars. All mRNA 
and protein values are normalized to β-actin expression. * indicates p≤0.05 ** 
indicates p≤0.01 
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 5.4 DISCUSSION 
The prediction of interactions between herbs and drugs is extremely important, given the 
increasing popularity of alternative medicines and the likelihood of co-administration of 
conventional drugs and herbal products. In vitro studies are therefore important tools to 
determine the interaction potential of different herbal components with conventional drugs 
through the modulation of drug metabolizing enzymes. Most natural products are complex 
mixtures of several different chemical compounds and commercial products are usually extracts 
of herbs rather than single components. In view of the multiplicity of various herbal components 
in the herbal preparations, herb-drug interactions may result from any number of herbal 
components. Therefore, predicting interactions with herbs is complicated. In general, it has 
become standard practice to study the inhibition potential of herbal compounds on major drug-
metabolizing enzymes. To date, all studies investigating the effects of valerian on drugs have 
been performed in cell-free systems such as expressed enzymes or human liver microsomes 
(Lefebvre, Foster et al. 2004; Strandell, Neil et al. 2004).  Since these models lack cellular 
integrity, they are incapable of predicting effects of the herbs on gene expression.  
Recent studies with natural products have clearly shown the utility of studying both 
inhibition and induction. For example studies in hepatocytes have shown the dual effect of St. 
John’s Wort constituent hyperforin on CYP3A4 enzyme (Komoroski, Zhang et al. 2004 ). In that 
study, hyperforin was shown to induce CYP3A4 on chronic treatment and inhibit the enzyme on 
acute treatment. A similar study employed primary cultures of hepatocytes to study the effects of 
drugs as well as natural products on CYP3A expression (Raucy 2003). Another study utilized 
human hepatocyte cultures to show that bergamottin, a grapefruit juice component, causes 
inhibition of P450s activities while increasing P450 proteins and mRNA levels (Wen, Sahi et al. 
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 2002).  These studies clearly demonstrate that hepatocytes are excellent models to study enzyme 
induction as well as inhibition by both therapeutic agents and natural products. 
Compounds in botanicals have been shown to alter the expression of drug metabolizing 
enzymes through various nuclear receptors. Terpenoids have been used as chemopreventive 
agents and monoterpenes such as limonene have been shown to induce drug metabolizing 
enzymes in animal studies (Maltzman, Christou et al. 1991). Other phenolic compounds such as 
flavonoids have also been shown to induce both phase I and phase II enzymes. Table 12 lists the 
various herbs with the respective chemical component and the nuclear receptors they are known 
to bind, suggesting that these herbs are capable of modulating the expression of genes regulated 
by the specific nuclear receptor.  
In our study, treatments with valerenic acid at 50µM concentration did not cause 
significant inhibition on acute treatment or induction on chronic treatment. Similar effects were 
observed with the alcoholic extract on acute treatment.  However, the dichloromethane extract 
and ethyl acetate extracts, which are devoid of the aqueous components, showed significant 
inhibition as well as induction effects.  
Effects on gene expression after chronic treatments were evaluated by measuring mRNA 
levels of UGT1A6 and UGT1A9 in cells treated with valerian acid and valerian extracts. For 
UGT1A6, valerenic acid and dichloromethane and ethyl acetate extracts caused a significant 
increase in mRNA levels.  Similarly, the dichloromethane and ethyl acetate extracts caused a 
significant increase in UGT1A9 mRNA levels, while valerenic acid and the alcoholic extract did 
not alter the mRNA levels. 
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 Table 12  Compounds in herbal products and nuclear receptors they bind 
Herb Compound Receptor 
Rhei rhizoma Lindleyin ER 
Ginseng Ginsenoside-Rg1 ER 
Grapeseed/red wine Resveratrol  ER 
Scutellaria baicalensis Baicalein AR 
Dioscorea villosa Diosgenin PR 
Longmu Zhuanggu Chongji Vitamin D2 VDR 
Xiao Chai Hu Tang  Retinoic acid RAR 
Guggul tree resin  Guggulsterone FXR 
Pseudolarix kaempferi  Pseudolaric acid B PPARα 
Hypericum perforatum  Hyperforin PXR  
Artemisia capillaris Dimethylesculetin CAR  
Soy  Genistein ER, AR, PR 
Labiatae  Isoprenoids PPARα/γ 
 
Modified from Lazar, M A, East meets West: an herbal tea finds a receptor, Journal of Clinical 
Investigation, 2004, 113(1):23-25  
 
These results indicate that the sesquiterpenes in the dichloromethane and ethyl acetate 
extracts of valerian are mild inducers of UGTs perhaps by activation of nuclear receptors PXR 
and CAR. The results of the hepatocyte experiments support our hypothesis that the induction of 
enzymes after chronic treatment is compensated by inhibition on acute treatment. These results 
provide the reason for our observations in the in vivo study demonstrating that hepatocytes are a 
better model system than human liver microsomes for investigating drug interactions.  
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 6.0  CONCLUSIONS AND FUTURE DIRECTIONS  
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 The purpose of this research was to investigate the potential of valerian to interact with 
drugs undergoing metabolism by phase II pathway via glucuronidation. In order to achieve this 
goal various approaches were utilized including isolated subcellular preparation, whole cell 
preparation and healthy human volunteers. Acetaminophen was used as a marker substrate to 
study glucuronidation since it undergoes extensive metabolism by this pathway. In order to 
measure the levels of acetaminophen and its metabolites in plasma an HPLC assay was 
developed and validated. A bioassay-guided fractionation method using human liver microsomes 
was adopted to isolate the potential constituents that could inhibit glucuronidation. This study 
was followed by an in vivo investigation of the effect of valerian preparations on acetaminophen 
pharmacokinetics in healthy human volunteers. In order to unravel the findings of the in vivo 
studies human hepatocyte cultures were used to evaluate the effects of acute and chronic 
exposure to valerian extracts on the expression and activity of UGT1A6/9 enzymes. 
 
Given the increasing popularity of herbal products and the emerging evidence of herb-
drug interactions, several in vitro studies have been performed to investigate the potential for 
herb drug interactions. Most studies are performed with whole herb preparations, making it 
difficult to conclusively attribute the interaction potential to any one component. In some studies, 
a single constituent believed to be the major constituent is investigated. As herbal products are 
often complex mixtures of multiple compounds, it is difficult to arrive at specific conclusions 
regarding their potential interactions based on theses studies. A bioassay guided approach aids 
the identification of the potential for interactions as wells as helps to identify the compound 
involved in this interaction process. This method was therefore adopted to isolate the fractions 
and identify the compounds in the active fractions that are responsible for alteration of 
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 metabolism. Most plant derived compounds posses poly- phenol moieties capable of conjugation 
with glucuronides or sulfates. In our studies, the potential to alter glucuronidation was 
investigated because valerenic acid is conjugated with glucuronide in human liver microsomes 
and is therefore likely to alter metabolism of substrates by this pathway. As is the case in most 
preliminary studies, human liver microsomes were used as the model system because of its ease 
of preparation and availability. These experiments indicated that the organic fraction of the 
valerian extracts inhibit acetaminophen glucuronidation. The major compounds in the organic 
extracts were identified by means of various spectrometric and chromatographic methods as 
valerenic acid, acetoxyvalerenic acid and valerenal. These results are in agreement with previous 
studies that also identified the major compounds in the dichloromethane extracts to be valerenic 
acid, acetoxyvalerenic acid and valerenal. 
 
Acetaminophen was used as a probe substrate to measure glucuronidation activity in our 
studies. In addition to being safe, predominantly metabolized by glucuronidation and having a 
short half life, the advantage of acetaminophen as a probe is that it can be evaluated in  in vitro 
as well as in vivo studies. A previously developed HPLC method was utilized to measure 
acetaminophen and acetaminophen glucuronide in microsomal incubations. However, this 
method had to be modified in order to be able to measure acetaminophen, acetaminophen 
glucuronide and acetaminophen sulfate in plasma. The modified method using ultraviolet 
detection was developed and validated. The advantages of this method are its simplicity and 
sensitivity, especially since a low dose of acetaminophen was administered in the clinical study. 
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 Based on the results of our studies with human liver microsomes we anticipated an in 
vivo interaction with acetaminophen, a UGT1A6/9 substrate. Our hypothesis for this study was 
that simultaneous administration of valerian and acetaminophen would cause an increase in 
acetaminophen AUC and Cmax. Subjects were asked to self administer valerian capsules at 
bedtime for a week prior to the study day in order to evaluate the effect of chronic administration 
of valerian. Analysis of the pharmacokinetic parameter of acetaminophen indicated that valerian 
administration did not alter the AUC or half life of acetaminophen in human volunteers. 
However, valerian administration increased the peak plasma acetaminophen concentration 
(Cmax) and reduced the time to reach the peak concentration (tmax) indicating that valerian 
increased the rate of absorption of acetaminophen. A similar effect was reported with a study 
using alprozolam as a probe substrate for CYP3A4 and  a similar effect was observed in our 
study investigating the effect of valerian on pharmacokinetics and pharmacodynamic of with 
lorazepam (unpublished). Collectively, these results indicate that valerian is capable of 
increasing gut motility resulting in increased rate of absorption of drugs from the gut. 
 
Given the differences in results obtained from the microsomal study and the in vivo 
human study we further evaluated the interaction potential of valerian extracts in human 
hepatocyte cultures. Hepatocyte culture system is more reliable model in investigating the 
interaction potential of durgs. As a result of preservation of cellular integrity it is possible to 
investigate not only effects of enzyme inhibition but also enzyme induction. The hypothesis for 
our study was that valerian and its extracts would inhibit UGT1A6 and UGT1A9 on chronic and 
acute exposure. The alcoholic extracts of valerian did not cause significant inhibition and only a 
marginal induction of acetaminophen glucuronide, consistent with the results observed in the 
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 clinical study. However, the organic extracts especially the ethyl acetate extracts showed 
significant inhibition of acetaminophen glucuronidation on acute exposure. However, on chronic 
exposure, these extracts caused a significant induction of acetaminophen glucuronide formation. 
Investigation of the mechanism of this induction was performed by quantification of mRNA 
levels of UGT1A6 and 1A9. The increase in mRNA levels was proportional to the observed 
increase in glucuronidation activity. This indicates that the induction of the enzymes is possibly 
through in-direct pathways, perhaps by the activation of nuclear receptors controlling the levels 
of these enzymes.  
 
Based on our studies with human volunteers valerian does not appear to significantly 
alter glucuronidation. Therefore, it may be safe to administer valerian with drugs undergoing 
glucuronidation by UGT1A6/9.  With regards to models for study of herb drug interactions, 
whole cell systems such as hepatocyte cultures are better than human liver microsomes to predict 
herb-drug interactions. The novel bioassay guided approach is advantageous compared to the 
whole herb extract or single compound investigations because of the variation in the herbal 
product preparations in the market.  Identifying compounds in herbal formulations that have the 
potential to alter drug metabolizing enzymes can help evalutions of these products based on their 
composition. 
 
Future research is required to identify the isozymes responsible for glucuronidation of 
valerenic acid.  Also very little information is available regarding the pharmacokinetics and 
bioavailability of herbal products in general and valerian in particular. A study to determine the 
pharmacokinetics of the major compounds in valerian products is required. In vitro and in vivo 
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 studies need to be performed in order to characterize the absorption of valerian compounds. In 
order to evaluate the effects of chronic exposure to valerian extracts followed by an acute 
exposure, an appropriately designed hepatocyte study is required. Although a pharmacokinetic 
interaction can be ruled out based on our findings, a pharmacodynamic interaction is possible 
with drugs with similar effects. Valerian being a sedative is anticipated to increase the potency of 
anesthetic agents such as midazolam or other sedatives such as lorazepam. A clinical study to 
confirm these potential interactions is warranted in the future. 
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 APPENDIX A 
EFFECT OF VALERIAN ON THE PHARMACOKINETICS OF ACETAMINOPHEN 
STUDY PROTOCOL, INFORMED CONSENT, ADVERTISEMENT, AND APPROVAL 
LETTER 
A. Names of Principal Investigator and Co-Investigators 
Principal Investigator:   Raman Venkataramanan, Ph.D. 
Co-Investigators: Mordechai Rabinovitz, M.D., Reginald Frye, PharmD., Ph.D. 
  Rama Sivasubramanian, M.Pharm.  
 
B. Protocol Title: Effect of Valerian on the pharmacokinetics of Acetaminophen. 
 
C. Specific aim  
The specific aim of this proposal is to evaluate the effect of valerian on the pharmacokinetics of 
acetaminophen in normal healthy subjects. The hypothesis is that the constituents in valerian extract 
will inhibit a glucuronide conjugating enzyme system (UGT1A6/9) that is responsible for 
conjugation of acetaminophen and will therefore reduce the clearance of acetaminophen from the 
body. 
 
D. Background Information and Significance 
Background Information:  
The prevalence of herbal product usage and alternative therapies has steadily increased in the recent 
years. Consumer spending on herbal products in the United States is estimated to be more than $5 
billion/year (1). More than one third of Americans use herbal products and a majority of these are 
patients with psychiatric disorders. The most commonly purchased herbal products are St. John’s 
wort, ginko biloba, ginseng, valerian root and chamomile. The use of an herbal product (or “natural 
product” as often advertised) as a sleep-aid and as an anxiolytic presents an attractive alternative 
remedy to some people. In fact, insomnia, depression and anxiety are the most common reasons for 
seeking alternative or complementary therapies. This raises concerns about unintended interactions 
between herbal medications and conventional therapies (2-4). Nearly 70% of the patients do not 
reveal their herbal use to physicians and pharmacists, making it difficult to identify herb-drug 
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 interactions in patients (5). In addition, herbal products are not regulated by the FDA for quality or 
consistency. Identification of herb-drug interactions is essential in order to improve the safety of 
therapeutic agents.  
Herbal products contain various chemical constituents. The elimination of exogenous chemicals 
including herbal components and several drugs is mediated through an array of drug and 
xenobiotic metabolizing enzymes. Glucuronidation is a major metabolic pathway that involves 
the transfer of glucuronic acid from uridine 5´-diphosphoglucuronic acid (UDPGA) to a 
multitude of endogenous and exogenous substrates including bilirubin, bile acids, steroid and 
thyroid hormones, drugs, pesticides, and carcinogens (6, 7). Uridine 5´-diphosphate [UDP]-
glucuronosyltransferases (UGTs) enzymes are distributed throughout the body and are found in 
liver, kidney, intestine, stomach, brain, and skin. The liver and intestine are major sites of 
glucuronidation in the body due to the diverse and abundant expression of UGT enzymes. Drugs 
and herbal components can interact in the intestine and or at the liver and alter the 
pharmacokinetics of a drug. In this study we plan to evaluate the interaction between valerian, a 
commonly used herbal product and acetaminophen, a commonly used analgesic.  
Valerian is one of the most commonly used herbal products to treat insomnia and anxiety. The 
products may contain the powdered plant material but more commonly a dried extract, which are 
sometimes standardized to a minimum level of particular constituents, usually valerenic acid. 
Consistency of valerian content will be maintained by using PharmAssure brand valerian 
capsules bearing the same batch number through out the study. This product has been analyzed 
and verified in our laboratory to contain 0.8% of valerenic acid, consistent with the amount 
stated on the label. Valerian extracts contain more than 100 different constituents including 
mixture of valepotriates and volatile oils. Substantial amounts of free amino acids; particularly 
gamma amino butyric acid GABA, tyrosine, arginine, and glutamine are also present in aqueous 
extract of the roots of valerian (8). Valerian has been shown to have sleep-inducing properties, 
anti-anxiolytic and tranquilizing effects both in animals and humans (9-12). In healthy human 
subjects, 400-900 mg daily of valerian extracts decreased sleep latency and nocturnal 
awakenings and improved the quality of sleep (12-14). Although the extracts produce significant 
effects, these are generally not seen until 2-3 weeks of therapy. The mechanism by which 
valerian exerts its tranquilizing or anxiolytic effect is not fully known, but in vitro receptor-
binding studies have found valerian to increase neuronal release of GABA, decrease GABA 
reuptake, and decrease GABA degradation. Additionally, valerian has agonist activity on the 
GABA-receptor complex (15, 16). Valerenic acid itself has also been shown to increase 
pentobarbital-induced sleeping time in animals. Valerenic acid increases GABA levels by 
inhibiting its metabolism, which is associated with sedation and a decrease in central nervous 
system (CNS) activity (8). Additionally, kessyl alcohol, another volatile oil constituent of 
valerian, and valepotriates possess sleep-inducing and anxiolytic properties (8). 
Valerenic acid is conjugated to a glucuronide metabolite in human liver microsomal system 
(personal observation). Acetaminophen is largely eliminated from the body by UGTs, including 
the UGT1A6 and 1A9. We have observed 80% reduction in UGT1A6/9 activity as measured by 
acetaminophen glucuronide formation in human liver microsomes treated with valerenic acid. 
These results indicate that both acetaminophen and valerian are eliminated by the same 
metabolic pathway, and therefore valerian could potentially modify acetaminophen 
pharmacokinetics in vivo. Acetaminophen was chosen because it is a commonly used analgesic 
that is extensively glucuronidated. 
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 Significance: This is a pilot study to gather data on the feasibility and the potential for valerian 
extract to alter the pharmacokinetics of acetaminophen. The widespread availability and use of 
herbal remedies including valerian makes it imperative that the potential for interactions with 
conventional therapies be clearly defined. 
Progress Report and Preliminary Studies 
Methanolic extracts of valerian capsules, as well as pure valerenic acid, significantly inhibited 
the glucuronidation of estradiol (UGT1A1), acetaminophen (UGT1A6/9), morphine (UGT2B7), 
and testosterone (UGT2B15). The magnitude of inhibition ranged from 30% to 80% depending 
on the probe drug and the extract concentration. These in vitro observations strongly support the  
 
need for further studies in vivo to determine whether the inhibition is of any clinical relevance 
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Research Design and Methods 
 
Drug Information 
The herbal product Valerian will be used in this investigation. We believe that an IND submission 
is not required for this study for the following reasons: 
This product is available over-the counter in pharmacies and health food stores making it easily 
available to the public. These products do not require FDA approval. 
This investigation is not intended to be reported to the FDA in support of a new indication for the 
use of Valerian and will not support any other significant change in the labeling of the product 
marketed. 
This study will not support any significant changes in the advertising for this marketed product. 
This study does not involve a route of administration or dosage level that significantly increases 
the risks associated with this marketed product. 
Study Design and Methods 
Screening Visit 1: 
Informed consent will be obtained from all subjects prior to participation in this study. Each 
subject will have to pass a screening evaluation based on history, physical examination and the 
following biochemical and urinalysis tests: BUN, creatinine, serum albumin, SGOT, SGPT, 
bilirubin and normal hematocrit ( males:40-52% females:35-47%). The screening visit will last 
approximately one (1) hour and 10 ml of blood will be drawn for biochemical measures to assess 
liver and kidney status. To participate, the subjects must not have any evidence of abnormal 
renal function (creatinine clearance estimated by Cockcroft-Gault method < 80 ml/min) or 
hepatic function (liver enzymes greater than 2.0-times the upper limit of normal or total bilirubin 
out of the normal range). In females, spot urine (spontaneous sample) sample will also be 
obtained for test for pregnancy. Age, height, and weight will be recorded in a demographic 
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 record. Once subjects are determined eligible they will return to the GCRC for study visit 1 
within one month of the screening visit. 
 
Study Design overview 
Healthy volunteers will be recruited to participate in this study such that at least eight subjects will 
complete the study.  This study will require eight study days and five outpatient visits to the 
GCRC. The two visits will be separated by one week.  Subjects will be instructed to abstain from 
taking any alcoholic beverages during the entire study. Subjects will be asked to abstain from 
taking caffeine containing beverages for 24 hours prior to and during the study visits and grapefruit 
or grapefruit juice 48 hours prior to and during the study visits. 
  
Study Visit 2 (day 1): Subjects will report to the General Clinical Research Center by 7:00 AM on 
the day of the study. They will be instructed to fast from midnight, the night before. Subjects will 
be asked to empty their bladder; women will be given a urine pregnancy test at this time. An 
intravenous catheter will be inserted for the purposes of blood collection. A single oral dose of 
acetaminophen (500 mg) will be administered with 8 ounces of water at 8.00 AM. Subjects will be 
asked to comply with the instructions and study coordinator will ensure that subjects adhere to the 
study protocol. Nine venous blood samples (N= 9, 3 ml each) will be drawn at 0 (before the dose), 
at 15, 30min, 1, 2, 3, 4, 6, and 8 hr from an indwelling catheter into vacutainer tubes for 
measurement of acetaminophen, valerenic acid and metabolites of acetaminophen and valerenic 
acid. Total urine output will be collected in intervals from 0-8 and 8-24 hrs after acetaminophen 
administration. At approximately 10:00 AM subjects will be given a light snack, and after 
approximately 12:00 PM, subjects may eat per normal schedule. The subjects may drink water as 
needed. Subjects will be discharged from the GCRC after the 8-hour blood and urine collections 
are completed. Subjects will be given a urine collection container to collect all urine out put up to 
24 hrs and asked to bring it to the GCRC the day after the study (visit 3). All urine samples will be 
tested for acetaminophen, acetaminophen glucuronide and valerenic acid levels. 
 
Study days 2-7:  Subjects will be provided with twelve (12) Valerian capsules (PharmAssure), 250 
mg containing 2mg of Valerenic acid and will be instructed to self-administer two capsules daily 
within two hours of bedtime. Subjects will be instructed to keep a diary and note the times at which 
the dose was taken on each night in order to monitor compliance. 
 
Study visit 4 and 5 (day 8 and 9): Subjects will report to the General Clinical Research Center by 
7.00AM. Subjects will be given two capsules of Valerian 250mg containing 2mg valerenic acid at 
8.00AM along with the dose of acetaminophen (500 mg) and subsequently undergo procedures as 
in visit 1.  The additional dose of valerian is given in order to maximize the drug interaction 
potential. 
 
Monitoring/Follow-up Procedures: 
For this research study, the monitoring/follow-up procedures include measurement of blood 
pressure, temperature, and heart rate at 3 and 8 hours after the administration of acetaminophen. 
All blood samples will be placed on ice immediately after collection and centrifuged within 15 
minutes. The resultant plasma will be stored at -20oC or lower until analyzed. Urine samples will 
be stored refrigerated until the end of the collection interval; after collection, the total volume will 
be measured and aliquots will be frozen at -20oC or lower until analyzed. A total of eighteen (18) 
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 blood samples per subject will be obtained over the course of this study. The total amount of blood 
withdrawn for all acetaminophen study days, including the screening labs, will be 64ml (about 2.1 
ounces or about 4 1/2 tablespoonfuls). After completion of the study the specimens of plasma and 
urine samples will be stored indefinitely in freezers in the pharmacokinetics laboratory under the 
control of the principal investigator of this research project. The samples will be assigned code 
numbers and the information linking these code numbers to the corresponding subjects will be kept 
in a separate, secure location. If a subject decides to withdraw or is eliminated from the study, the 
specimens obtained will be destroyed. Samples will not be given to secondary investigators.  
However, patients can give permission to be re-contacted to obtain consent to use their samples for 
other research projects.  
Analytical Procedures 
Drug analysis: Plasma and urine concentrations of acetaminophen, its glucuronide conjugate, its 
sulfate conjugate and valerenic acid will be determined using an HPLC method developed in our 
laboratory. 
Data Analysis 
The pharmacokinetic parameters of acetaminophen will be determined by non-compartmental 
methods. The elimination rate constant (k) will be obtained using nonlinear least-square 
regression of the terminal concentration-time data. The area under the concentration versus time 
curve (AUC) will be calculated by trapezoidal rule with extrapolation to infinity. Acetaminophen 
apparent oral clearance (CL/F) will be determined as dose/AUC and apparent volume of 
distribution will be determined for acetaminophen as dose/AUC x k. The urinary recovery of 
acetaminophen, acetaminophen glucuronide (AUAPAPG) and acetaminophen sulfate from 0-24 
hours will also be determined. Fractional metabolic clearance for each pathway will also be 
calculated. Valerenic acid concentrations in plasma will be determined to allow for comparison 
to the in vitro inhibition data. The maximum observed plasma concentration (C max) and plasma 
AUC of valerenic acid will be calculated and correlated with % change in the clearance of 
acetaminophen. 
G. Biostatistical Design and Analysis  
Sample Size and Power: This is a pilot study to evaluate the potential for an interaction between 
valerian and acetaminophen. Taking into account the low intraindividual coefficient of variation of 
acetaminophen pharmacokinetic parameters (usually below 20%), a sample size of 8 subjects 
attained a power of 0.8 and an alpha of 0.05 to determine a 25% change in acetaminophen 
clearance. 
Statistical analysis: The pharmacokinetic data being calculated include AUC0-α, Cmax, apparent 
oral clearance, metabolic ratio (AUC of metabolite to parent drug concentration in the plasma), 
total urinary excretion of metabolites and fractional metabolic clearance. Paired t test will be used 
to evaluate the significance of the differences in the parameters measured at a p ≤ 0.05.  
 
H. Recruitment Methods and Consent Procedures:  
 Subject population 
The study will be conducted in 8 healthy subjects (4 men/4 women), 18 – 65 years, and will 
involve the evaluation of the pharmacokinetics of orally administered acetaminophen before and 
during administration of Valerian. Based on past experience, we anticipate a screening failure rate 
of approximately 30%, thus the proposed number of subjects to be enrolled per IRB guidelines will 
be twelve, which allows for potential dropout of 4 subjects. Attempts will be made to recruit even 
numbers of men and women. In the event that we are unable to recruit equal number of both 
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 genders with in 8 months, subjects will be recruited as received. All subjects enrolled will give 
written informed consent.  As defined by NIH, this study will enroll children aged 18 to 21 years; 
children less than 18 years of age will be excluded from study participation. 
Each subject will have to pass a screening evaluation based on history, physical examination and 
the following biochemical and urinalysis tests: BUN, creatinine, serum albumin, SGOT, SGPT, 
total bilirubin and hematocrit. Pregnant women, or women who are currently breast-feeding an 
infant, will not be allowed to take part in this study. Women of childbearing potential will be tested 
to exclude pregnancy using a urine pregnancy test. Use of estrogen and progestational hormone 
agents will be permitted.   
Acetaminophen (Tylenol Extra strength) and Valerian (PharmAssure brand) will be provided at no 
cost to all participants for the study period by the investigator.  Valerian is classified as a dietary 
supplement and its use is not approved by the FDA. 
Inclusion Criteria:  
Non-smokers (self-reported) between the ages of 18-65 years. 
Signed Informed Consent. 
Body Mass Index (BMI) < 31. 
Normal hematocrit (males: 40-52% females: 35-47%) 
 Exclusion Criteria 
a. Evidence of renal dysfunction (estimated creatinine clearance < 80ml/min). 
b. Impaired hepatic function (liver enzymes greater than two times the upper limit of normal 
or total bilirubin > 2.0 mg/dl). 
Taking any medications other than oral contraceptives (for women) 
Currently taking any herbal medicines 
Women who are pregnant or are currently breastfeeding. 
Blood donators within 2 months prior to the study 
Patients with known G6PD deficiency 
Subjects will be recruited through an advertisement (approved by the IRB) that will be placed in 
different locations in the University campus and in the Pitt News. We have requested and 
obtained a waiver of the requirement to obtain signed informed consent for the screening 
process, which will take place over the phone.  We believe we meet the following criteria:  The 
respective research procedures present no more than minimal risk of harm to the involved 
subjects and involve no procedures for which written consent is normally required outside of the 
research context.  The information being obtained during the screening phone call is only to 
determine the eligibility of the subject for further participation in this study. Please refer to 
Appendix A for the screening script and screening tool that will be utilized.  If the subject is not 
eligible for the study he/she will be so notified and the screening data will be destroyed. If the 
subject is eligible for study he/she will be so informed and scheduled for screening visit. Cold 
calling will not be used to recruit subjects. Informed Consent will be obtained prior to any 
screening procedures. Subjects considering enrollment in the study will be provided with an IRB 
approved consent form to read, and the study protocol will be explained to them. Any questions 
that the potential subjects have will be answered by a physician co-investigator. If interested in 
study participation, subjects will be asked to sign the consent form.  A copy will be maintained 
in the subject’s GCRC chart and a copy retained by the investigator. A physician co-investigator 
will obtain consent and sign the certification of informed consent.  Eligible subjects will then 
undergo a screening assessment based on history, physical examination and laboratory tests to 
assess their suitability for the study.  
 117 
 Gender and Minority Inclusion Statement:   
Women or men of all races will be eligible and recruited for this study.    The racial and age mix 
of the study will be representative of the population of Western Pennsylvania. There will be no 
exclusion based on race, sex, or ethnicity. 
Child Exclusion Statement:  
Children below the age of 18 will be excluded from this study as Valerian is not commonly used 
to treat children and therefore this research topic is irrelevant to children. 
2. Total Planned Enrollment: 8 
TARGETED/PLANNED ENROLLMENT: Number of Subjects 
Sex/Gender Ethnic Category Females Males Total 
 Hispanic or Latino       
 Not Hispanic or Latino 4 4 8 
 Ethnic Category Total of All Subjects* 4 4 8 
Racial Categories  
 American Indian/Alaska Native       
 Asian 0 0 0 
 Native Hawaiian or Other Pacific Islander                    
 Black or African American  1 1 2 
 White 3 3 6 
 Racial Categories: Total of All Subjects * 4 4 8 
 
3. Sources of Research Material 
Subjects who participate in this study will provide medical information along with blood and 
urine samples. The blood and urine samples will be obtained specifically for research purposes in 
order to meet our specific aim.   
4.   Recruitment Methods and Consent Procedures: 
Subjects for this study will be recruited via advertisement. The study consent form will be 
presented by Mordechi Rabinovitz, M.D., and subjects will be asked to provide informed consent 
to participate in the pharmacokinetic study prior to any research procedures. 
5. Risk/Benefit Ratio 
The risks involved with this study include the discomfort and inconvenience of having an 
intravenous catheter placed and blood samples collected with potential for pain, bruising, 
bleeding and infection.  Side effects are listed below for each of the drugs used in this study.  
Side effects that are considered likely occur in more than 25 out of every 100 (25%) people who 
take the drug, common side effects occur in approximately 1 to 25% of people, and rare side 
effects occur in less than 1% of people.  Additional information in the form of patient education 
leaflets is available in the appendices.  These will be made available to study subjects. 
 
Valerian capsules (PharmAssure) containing valerian root extract (250 mg) is an over-the-
counter product used to treat insomnia and anxiety.  Valerian products have been shown to be 
generally safe, even when fairly large doses as much as twenty times the daily-recommended 
dose was taken (6-20g)(17). Adverse reactions to valerian preparations are rare (5).  
  Likely:       None. 
 Common: Valerian may cause headache, excitability, uneasiness, insomnia, mydriasis, and 
daytime sedation. 
 118 
 Rare:   Paradoxical stimulation (including restlessness and palpitation) and hepatotoxicity have 
been experienced by a small percentage of consumers after long-term consumption 
Acetaminophen (Tylenol Extra Strength) containing 500 mg is a common over-the -counter, 
FDA approved drug for treatment of pain and fever.  
Likely:         None  
Common:    None 
Rare:      Acetaminophen may cause hematologic, allergic or other miscellaneous     adverse 
effects; 
Hematologic: Methemoglobinemia, hemolytic anemia neutropenia, thrombocytopenia, 
pancytopenia, and leukopenia. At very high doses (greater than 4g per day over a long term 
period), acetaminophen can cause liver damage. 
Allergic: Urticarial and erythematous skin reactions, skin eruptions, fever. 
Miscellaneous: CNS stimulation, rare blood disorders, hypoglycemic coma, jaundice, 
drowsiness, and glossitis. Possible liver damage in those who consume three or more alcoholic 
drinks daily.  
 
No personal benefit will result from this study. Information obtained from this study, however, will 
provide increased knowledge about the potential effect of valerian on metabolism of drugs through 
UGT1A6/9 enzyme system. There is the inconvenience of participating in the study, collecting 
urine and having blood withdrawn. There is a minor risk of developing bruises associated with 
blood sampling. Pregnancy will not be permitted during the study due to unknown adverse events 
that could occur. 
 
The research coordinator will monitor any adverse events in the subjects participating in this study 
and report occurrence of any events to the  Institutional Review Board (IRB) immediately. 
 
Any information obtained about the subjects for this research study will be kept confidential.   
Subject records will be indicated by a case number rather than by subject's name and the 
information linking these case numbers with the subject's identity will be kept separate from the 
research records.   
   
6. Risk Management Procedures: The risk of adverse experiences in this study will be 
minimized by utilizing only qualified individuals to conduct the study, the staff in GCRC in 
UPMC-MUH.  Appropriate attention to detail in the experimental setting will be emphasized.  
Moreover, this study will use small, single doses of acetaminophen and short-term exposure to 
valerian and thus, the likelihood of dose-related adverse events should be minimized.  In the 
event that a subject experiences an intolerable side effect, the subject will be withdrawn from the 
study and followed for resolution of the effect(s). A subject may also be removed from the study 
if in the opinion of the physician investigator; it is in the subject’s best interest. 
  
7. Data Safety Monitoring Plan.  This study involves a small number of subjects who will 
be closely monitored by the investigators and research personnel on the General Clinical 
Research Unit. The data and safety information obtained in each study subject will be reviewed 
at a weekly or biweekly meeting held by the investigators. As a part of these meetings, the 
research team will monitor data, confidentiality, and recruitment in addition to adverse events. A 
summary report from the meetings will be submitted to the IRB at the time of annual renewal. 
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 We will comply with the IRB’s policies for the reporting of serious and unexpected adverse 
events as detailed in Chapter 3.0, sections 3.4 and 3.5 of the IRB Reference Manual. If a serious 
life-threatening event occurs, the event will be reported immediately (i.e., within 24 hours) to 
both the FDA and the IRB.  Unexpected reactions of moderate or greater severity will be 
reported to the IRB within 10 calendar days of the reaction. Minor events will be reported to the 
IRB at the time of annual review. All records related to the subjects in this research study will be 
stored in a locked file cabinet.  Access to the research records will be limited to the researchers 
listed on the first page.  Subjects will not be identified by name in any publication of the research 
results unless the subjects sign a separate release form. 
 
8. Costs and Payments 
The subjects will not be charged for any studies related to this protocol. The subject's insurance 
will not be billed for this study. Subjects who participate will receive $ 50 for each part as 
reimbursement for expenses involved in participating in this study. The total compensation will be 
$ 100 for the two study periods. Subjects will be paid the entire amount when they bring the last 
urine sample on the day after the second visit. Funds from the pharmacokinetics laboratory will be 
used to cover these payments. 
I.   Justification for Utilization of GCRC Resources 
The GCRC use is being requested to utilize the facilities and expertise available to ensure proper 
execution of the study.  It will ensure that drugs are given under medical supervision and samples 
are collected by qualified professionals with experience in the conduct of research studies.  These 
factors are important to obtain results that are valid and interpretable. 
 
J.   Study Size and GCRC Resources 
1.  Number of Research Subjects: 12 (8 to complete) 
2. Total Number of Inpatient Days: 0 
3. Total Number of Outpatient Days:  12 screening + 16 outpatient visits 
4. Estimated Ancillary costs per IP day:  none 
5. Estimated Ancillary costs per OP day: $ 226.08 
   6. Description of other GCRC Resources Requested: Yes, Nursing and nutrition support      
requested. 
K. Research needs to be provided by Investigator’s laboratory 
Analytical assays required for the determination of concentrations of acetaminophen and its 
glucuronide will be conducted by Dr. Venkataramanan.  Labeled storage containers for 
plasma/urine samples will be provided to GCRC. 
L. Funding Support 
Funding from GCRC is requested for screening tests.  Funds in the Clinical Pharmacokinetics 
Laboratory and Center for Pharmacodynamics will be utilized for the study. 
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N. Qualifications of the Investigators 
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 Raman Venkataramanan Ph.D. is the director of the Clinical Pharmacokinetics Laboratory, and has 
conducted drug disposition studies in normal subjects, liver, heart, kidney and bone marrow 
transplant patients since 1982.  
Reginald Frye, PharmD., PhD. is an assistant professor at the School of Pharmacy, University of 
Florida and has expertise in the evaluation of drug metabolism in humans. 
Mordechi Rabinovitz, MD, is a gastroenterologist with extensive research experience in human 
subjects.  
Rama Sivasubramanian is a Ph.D. student in the Department of Pharmaceutical Sciences in the 
School of Pharmacy.  She will serve as the study coordinator.  
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 PROTOCOL APPENDIX A 
ADVERTISEMENT 
Healthy Volunteers Needed 
 
Researchers at the University of Pittsburgh are seeking healthy volunteers between 18 & 65 
years to take part in a study looking at how Valerian, an herbal product affects the elimination of 
Acetaminophen, a common pain reliever. A 1 hour screening visit to see if you are eligible and 
two one-day stays (1 or 2 weeks apart) in UPMC-Montefiore are required.  Participants will be 
paid $100 upon study completion.   
You may be eligible if you are 
• Between 18 & 65 years old 
• Healthy 
• Non-smoking 
• Not taking any medications or herbal products (except oral contraceptives) 
 
For more information  contact Rama Sivasubramanian, School of Pharmacy at 412-648-9436 or 
via email at  rasst95@pitt.edu . 
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CONSENT TO ACT AS A SUBJECT IN AN EXPERIMENTAL STUDY 
TITLE: Effect of valerian on the pharmacokinetics of acetaminophen  
 PRINCIPAL INVESTIGATOR:    Raman Venkataramanan, Ph.D.   
         Professor, School of Pharmacy 
         718 Salk Hall,   
         Tel:  412-648-8547 
CO-INVESTIGATORS: Mordechai Rabinovitz, M.D.  
 Assoc. Professor of Gastroenterology 
 3rd Floor Falk Clinic, School of Medicine  
 Tel: 412-383-8687 
 Reginald Frye, Pharm D., Ph. D. 
 Assoc. Professor  
 Univ. of Florida, College of Pharmacy
 Tel: 352-273-6238 
          Rama Sivasubramanian, M.Pharm.  
          Graduate Student, School of Pharmacy 
          806 Salk Hall,   
          412-648-9436  
SOURCE OF SUPPORT:                      Clinical Pharmacokinetics laboratory funds  
 
TO PERSONS WHO ARE INTERESTED IN PARTICIPATING IN THIS STUDY: 
The following information is provided to inform you about the research project and your 
participation in it. Please read this form carefully. Please feel free to ask any questions that you 
may have about this study and/or about the information given below. 
 
Why is this research being done? 
The purpose of this study is to determine if the herbal product, valerian root extract (valerian) 
changes the way the body removes a drug, acetaminophen.  Valerian is an herbal product sold 
over-the-counter and is used for sleep disorder and anxiety. Valerian is not approved by the Food 
and Drug Administration (FDA) as a drug, although it is sold in Health Food and Drug stores as 
a supplement and can be bought without a prescription. Acetaminophen (Tylenol®) is a common 
FDA approved over- the- counter pain reliever.  
 
  University of Pittsburgh 
  Institutional Review Board 
  IRB Number: 0312032 
  Approval Date: 12/17/2003 
  Renewal Date: 12/16/2004 
 
 
________________ 
Subject’s Initial 
 
125
Who is being asked to take part in this research study? 
You are being asked to participate in this research study because you are a healthy man or 
woman between 18-65 years of age. A total of eight healthy men and women will participate in 
this study. This study will require two (2) one day stays (each visit will last approximately 10 
hours) in the General Clinical Research Center (GCRC) in UPMC-Montefiore hospital. The 
stays will begin the morning of study day 1 and study day 8.    
What procedures will be performed for research purposes? 
Screening Procedure: 
If you decide to take part in this research study, you will first sign this informed consent. You will 
be required to spend approximately 1 hr initially to give your medical history and to give a blood 
sample (about 10 ml – two teaspoonfuls) to make sure that your red blood cell count is not low. 
You will also be required to give a spontaneous urine sample to assess your pregnancy status. You 
will take part in the experimental procedure if you meet the criteria for entry in to this study.  
Experimental Procedure: 
If you qualify to participate in this research study, you will have to come back to the General 
Clinical Research Center (GCRC) two more times.  For both visits, you will arrive at the GCRC at 
7.00 a.m. on the day of the study. You will be asked to abstain from taking any alcoholic beverages 
during the entire study. You will be asked to abstain from taking caffeine-containing beverages for 
24 hours prior to and during the study visits and grapefruit or grapefruit juice 48 hours prior to and 
during the study visits. If you are a woman urine pregnancy test will be performed prior to any 
blood sample collection at both visits. Procedures performed to evaluate the effectiveness and 
safety of the experimental procedures are called “monitoring” or “follow-up” procedures. For this 
research study, the monitoring/follow-up procedures include measurement of your blood pressure, 
temperature, and heart rate at 3 and 8 hours after the administration of acetaminophen. The total 
length of your stay in the GCRC will be approximately 10 hours per visit. 
Visit 1 
If you agree to participate, you will be instructed to fast from midnight the night before the visit 
and arrive at the GCRC at 7:00 a.m. on the day of the study. You will have a small plastic tube 
inserted into a vein in your arm or hand to help with the collection of blood samples. You will also 
be required to give a spontaneous urine sample to assess your pregnancy status. A quarter teaspoon 
of blood will be taken from this tube in your vein. This is done to obtain baseline information of 
your blood in the absence of any drugs. At 8.00 AM you will receive one dose of acetaminophen 
(500 mg) by mouth. After taking the medicine, quarter of teaspoon of blood will be taken at 
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various time points (8.15, 8.30, 9.00, 10.00, 11.00, 12.00, 2.00 & 4.00) from a tube in your vein 
during the day (total of about 2 tablespoons of blood) in order to determine the amount of 
acetaminophen, acetaminophen glucuronide and valerian products.  Your urine will also be 
collected from the time at which the medicine was given to time of last blood sample collection 
(i.e. 8.00 AM to 4.00 PM). You will be provided a light snack at 10.00 AM and you may resume 
you normal eating schedule with lunch at 12.00 PM. A container will be provided to you to collect 
urine for another 16 hrs (8-24 hrs) and you will be asked to bring it to the GCRC the day after the 
study. The urine samples will be tested for acetaminophen and valerian levels. You will be given 
12 valerian 250 mg capsules to take once a day until your next visit. You will take two valerian 
250 mg capsules within two hours of bedtime every day for six days. You will be provided with a 
diary to record the time at which the valerian dose was taken each night and will be asked to return 
the diary to the study coordinator at the time of your second visit.    
Visit 2 
One week after the first visit, you will arrive in the GCRC at 7:00 a.m. on the day of the study after 
an over night fast. You will also be required to give a spontaneous urine sample to assess your 
pregnancy status. You will be given an additional dose of valerian (two 250 mg capsules) at 7:00 
a.m. You will have a small plastic tube inserted into a vein in your arm or hand to help with the 
collection of blood samples. A quarter teaspoon of blood will be taken from this tube in your vein. 
This is done to obtain baseline information of your blood in the absence of any drugs. You will 
receive one dose of acetaminophen (500 mg) by mouth. Then, at various time points after taking 
the medicine, quarter of teaspoons of blood will be taken from a tube in your vein nine times 
during the day (total of about 2 tablespoon of blood).  Your urine will also be collected from the 
time at which the medicine was given to time of last blood sample collection (i.e. 8.00 AM to 4.00 
PM). A container will be provided to you to collect urine for another 16 hrs (8-24 hrs) and you will 
be asked to bring it to the GCRC the day after the study. 
Monitoring/Follow-up Procedures: 
Procedures performed to evaluate the effectiveness and safety of the experimental procedures are 
called “monitoring” or “follow-up” procedures.  For this research study, the monitoring/follow-up 
procedures include measurement of your blood pressure, temperature, and heart rate at 3 and 8 
hours after the administration of acetaminophen. 
After completion of the study your blood and urine samples will be stored indefinitely in freezers 
in the pharmacokinetics laboratory under the control of the principal investigator of this research 
project. Your blood and urine samples will not bear your name for identification; instead they will 
be assigned code numbers. Information linking these code numbers to your name will be kept 
separate in a secure location. If you decide to withdraw or are eliminated from the study, your 
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blood and urine samples will be destroyed. Your blood samples will not be given to secondary 
investigators.  However, you can give permission to be re-contacted to obtain consent to use your 
samples for other research projects. 
What are the possible risks, side effects, and discomforts of this research study? 
You will not experience any personal benefits as a result of your participation in this study. The 
possible risks of this research may be due to the study drug and/or the blood tests. As with any 
investigational study, there may be adverse events or side effects that are currently unknown and 
it is possible that certain of these unknown risks could be permanent, serious or life threatening. 
Risks of the Study Drugs: 
Acetaminophen is a common pain medication that has been safely used by large numbers of 
healthy adults but has not been given to subjects taking valerian in a research setting. The side 
effects listed for this drug are known primarily from the use of high doses rather than the two 
small doses that you will be taking.  The side effects and their frequencies are listed below: 
Side effects are listed below for each of the drugs used in this study.  Side effects that are 
considered likely occur in more than 10 out of every 100 (10%) people who take the drug, 
common side effects occur in approximately 1 to 10% of people, and rare side effects occur in 
less than 1% of people. 
Acetaminophen (Tylenol Extra Strength) containing 500 mg is a common over-the -counter, 
clinically proven analgesic agent.  
Likely: None  
Common:  None 
Rare: Acetaminophen may cause rare blood disorders (abnormal hemoglobin function, reduction 
in one or all blood cells), allergic reactions (such as rash, fever or hives) or other adverse effects 
such as excitement (central nervous system stimulation), tongue inflammation, drowsiness or 
jaundice (a condition where bilirubin builds up in the blood, causing a yellow color to the skin 
and whites of the eyes). Acetaminophen can also cause liver damage in those who consume three 
or more alcoholic drinks daily. 
Valerian capsules (PharmAssure) containing valerian root extract (250 mg) is an over-the-
counter product used to treat sleeplessness and anxiety.  Adverse reactions to valerian 
preparations are rare. 
Likely: None. 
Common:  Valerian may cause headache, excitability, uneasiness, insomnia(difficulty sleeping), 
mydriasis (dilated pupils), and daytime sedation. 
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Rare:  Unexpected stimulation including restlessness and palpitation (sensation of fast or 
irregular heartbeat) has been experienced by a small percentage of consumers after long-term 
consumption. Some liver problems in rare cases have also been associated with valerian use. 
While taking valerian, caution should be used when driving or operating machinery. 
 
Animal studies to determine the effects of valerian on the fetus(unborn child) have not been 
done. To avoid risk to the fetus, it is important that you (for female participants) or your sexual 
partner (for male participants) do not become pregnant during the research study. Avoiding 
sexual activity is the only certain method to prevent pregnancy. However, if you choose to be 
sexually active, you must agree to use an appropriate double barrier method of birth control 
(such as female use of a diaphragm, intrauterine device, sponge and spermicide), in addition to 
the male use of condom or involve the female use of prescribed ”birth control pills” or a 
prescribed birth control implant for at least two weeks after completion of the study. If you 
choose to be sexually active during the study you must accept the risk that pregnancy could still 
result, exposing you or your partner to potential loss of pregnancy as well as other unknown 
effects on the developing fetus.  
 
Women who are capable of getting pregnant will have a negative pregnancy test prior to start of 
the study. If you become aware that you are pregnant during the course of this research study, you 
understand that you must stop taking valerian at once. You agree to do so and to contact the 
principal investigator listed on the first page and your physician, immediately. 
 
If you are a man, it is recommended that you use an effective method of birth control while you are 
participating in the study and for 2 weeks following completion of the study. If you choose to be 
sexually active during this study you must accept the risk that pregnancy could still result, 
exposing you or your sexual partner to potential loss of pregnancy as well as other unknown effects 
on developing fetus. 
 
 
Risks due to blood tests 
The risks of participation in this study include the discomfort and inconvenience of having a plastic 
tube placed in your arm and possible lightheadedness from having some blood samples collected. 
Arm pain, bleeding, swelling, bruising and/or infection may result from having the plastic tube 
inserted in your arm and the blood withdrawal.  
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What are the possible benefits from taking part in this study? 
While you will not directly benefit from this study, all subjects who take valerian in the future may 
benefit from this study by our increased understanding of how the body handles drugs when used 
with valerian.  This may help us to predict how to dose drugs that are important for their care. 
 
If I agree to take part in this research study, will I be told of any new risks that may be found 
during the course of the study? 
 
You will be promptly notified if, during the conduct of this research study, any new information 
develops which may cause you to change your mind about continuing to participate. 
 
Will my insurance provider or I be charged for the costs of any procedures performed as part of 
this research study? 
 
Neither you, nor your insurance provider, will be charged for the costs of any of the procedures 
performed for the purpose of this research study. The study will cover the costs of the research 
services being provided. 
 
Will I be paid if I take part in this research study? 
 
For the study, valerian and acetaminophen will be provided to you by the investigators at no cost. 
Your parking will be provided to you at no cost at your screening visit. You will receive $50 
payment for each part of the study to help cover the cost for travel, meals, or lodging associated 
with participating in this study. The total payment for participation in the entire study will be $ 
100.  You will receive this payment when you bring the last urine sample to the GCRC. 
 
Who will pay if I am injured as a result of taking part in this study? 
 
University of Pittsburgh investigators and their associates who provide services at the University of 
Pittsburgh Medical Center (UPMC) recognize the importance of your voluntary participation to 
their research studies. These individuals and their staffs will make reasonable efforts to minimize, 
control, and treat any injuries that may arise as a result of this research. 
 
If you believe that you are injured as a result of the research procedures being performed, please 
contact immediately the Principal Investigator or one of the co-investigators listed on the first 
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page of this form. Emergency medical treatment for injuries solely and directly relating to your 
participation in this research will be provided to you by the hospitals of UPMC. It is possible that 
the UPMC may bill your insurance provider for the costs of this emergency treatment, but none 
of these costs will be charged directly to you. If your research related injury requires medical 
care beyond this emergency treatment, you will be responsible for the costs of this follow-up 
care unless otherwise specifically stated below. You will not receive monetary payment for, or 
associated with, any injury that you suffer in relation to this research. 
 
Who will know about my participation in this research study? 
 
Any information about you obtained from or for this research study will be kept as confidential 
(private) as possible.  All records related to your involvement in this research study will be stored 
in a locked file cabinet.  Your identity on these records will be indicated by a case number rather 
than by your name, and the information linking these case numbers with your identity will be kept 
separate from the research records.  Access to your research records will be limited to the 
researchers listed on the first page of this form.  You will not be identified by name in any 
publication of the research results unless you sign a separate form giving your permission 
(release). 
 
Will this research study involve the use or disclosure of my identifiable medical information? 
 
This research study will involve the recording of current and/or future identifiable medical 
information from your hospital and/or other (e.g., physician office) records. The information that 
will be recorded will be limited to information concerning your screening visit blood analysis 
and the levels of the two medications in your blood.  This information will be used for the 
purpose of identifying if a drug-interaction exists between the two study medications in 
otherwise healthy subjects.  
 
Who will have access to identifiable information related to my participation in this research 
study? 
 
In addition to the investigators listed on the first page of this authorization (consent) form and 
their research staff, the following individuals will or may have access to identifiable information 
(which may include your identifiable medical information) related to your participation in this 
research study:  
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Authorized representatives of the University of Pittsburgh Research Conduct and Compliance 
Office may review your identifiable research information (which may include your identifiable 
medical information) for the purpose of monitoring the appropriate conduct of this research 
study.  
 
In unusual cases, the investigators may be required to release identifiable information (which 
may include your identifiable medical information) related to your participation in this research 
study in response to an order from a court of law. If the investigators learn that you or someone 
with whom you are involved is in serious danger or potential harm, they will need to inform, as 
required by Pennsylvania law, the appropriate agencies. 
 
Authorized representatives of the U.S. Food and Drug Administration may review and/or obtain 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for the purpose of monitoring the accuracy of the 
research data. While the U.S. Food and Drug Administration understands the importance of 
maintaining the confidentiality of your identifiable research and medical information, the 
University of Pittsburgh and UPMC cannot guarantee the confidentiality of this information after 
it has been obtained by the U.S. Food and Drug Administration. 
 
Authorized representatives of the UPMC hospitals or other affiliated health care providers may 
have access to identifiable information (which may include your identifiable medical 
information) related to your participation in this research study for the purpose of (1) fulfilling 
orders, made by the investigators, for hospital and health care services (e.g., laboratory tests, 
diagnostic procedures) associated with research study participation; (2) addressing correct 
payment for tests and procedures ordered by the investigators; and/or (3) for internal hospital 
operations (i.e. quality assurance). 
 
For how long will the investigators be permitted to use and disclose identifiable information 
related to my participation in this research study? 
 
The investigators may continue to use and disclose, for the purposes described above, 
identifiable information (which may include your identifiable medical information) related to 
your participation in this research study for a period of five years.  
 
 
 
  University of Pittsburgh 
  Institutional Review Board 
  IRB Number: 0312032 
  Approval Date: 12/17/2003 
  Renewal Date: 12/16/2004 
 
 
________________ 
Subject’s Initial 
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Is my participation in this research study voluntary? 
 
Your participation in this research study, to include the use and disclosure of your identifiable 
information for the purposes described above, is completely voluntary. (Note, however, that if 
you do not provide your consent for the use and disclosure of your identifiable information for 
the purposes described above, you will not be allowed, in general, to participate in the research 
study.) Whether or not you provide your consent for participation in this research study will have 
no affect on your current or future relationship with the University of Pittsburgh. Whether or not 
you provide your consent for participation in this research study will have no affect on your 
current or future medical care at a UPMC Health System hospital or affiliated health care 
provider or your current or future relationship with a health care insurance provider. 
 
May I withdraw, at a future date, my consent for participation in this research study? 
 
You may withdraw, at any time, your consent for participation in this research study, to include 
the use and disclosure of your identifiable information for the purposes described above. (Note, 
however, that if you withdraw your consent for the use and disclosure of your identifiable 
information for the purposes described above, you will also be withdrawn, in general, from 
further participation in this research study.)  Any identifiable research information recorded for, 
or resulting from, your participation in this research study prior to the date that you formally 
withdrew your consent may continue to be used and disclosed by the investigators for the 
purposes described above.  
 
To formally withdraw your consent for participation in this research study you should provide a 
written and dated notice of this decision to the principal investigator of this research study at the 
address listed on the first page of this form.  
 
Your decision to withdraw your consent for participation in this research study will have no affect 
on your current or future relationship with the University of Pittsburgh. Your decision to withdraw 
your consent for participation in this research study will have no affect on your current or future 
medical care at a UPMC Health System hospital or affiliated health care provider or your current 
or future relationship with a health care insurance provider. 
 
 
 
  University of Pittsburgh 
  Institutional Review Board 
  IRB Number: 0312032 
  Approval Date: 12/17/2003 
  Renewal Date: 12/16/2004 
 
 
________________ 
Subject’s Initial 
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If I agree to take part in this research study, can I be removed from the study without my 
consent? 
 
It is possible that you may be removed from the research study by the researchers if, for example, 
your pregnancy test proves to be positive or you do not follow the instructions of the researchers. 
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********************************************************************** 
VOLUNTARY CONSENT    
 
All of the above has been explained to me and all of my current questions have been answered.  I 
understand that I am encouraged to ask questions about any aspect of this research study during the 
course of this study, and that such future questions will be answered by the researchers listed on 
the first page of this form. Any questions I have about my rights as a research participant will be 
answered by the Human Subject Protection Advocate of the IRB Office, University of Pittsburgh 
(412-578-8570).  By signing this form I agree to participate in this research study. 
I give my permission to be recontacted to obtain my consent if there a desire to use my de-
identified biological sample in other research projects involving the study of different conditions 
other than those specified in the Description section of this consent form. 
   YES _________________   NO_________________________ 
 
By signing this form, I agree to participate in this research study.  A copy of this consent form will 
be given to me. 
______________________________________       
Participant's signature      Date and time 
********************************************************************** 
CERTIFICATION OF INFORMED CONSENT 
 
I certify that I have explained the nature and purpose of this research study to the above-named 
individual(s), and I have discussed the potential benefits and possible risks of study participation.  
Any questions the individual(s) have about this study have been answered, and we will always be 
available to address future questions as they arise. 
 
______________________________________      _________ 
Printed Name of Person Obtaining Consent   Role in Research Study 
 
 ______________________________________          
Signature of Person Obtaining Consent              Date and Time 
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